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ABSTRACT 
Magnetotactic Bacteria (MTB) are being explored as potential drug transporters to solid tumours. 
The MTB’s active motility combined with magnetotaxism (their ability to swim following the 
direction of a magnetic field) offer new and potentially more accurate solutions in delivering 
drugs to tumours. In fact, the flagella bundles of the MC-1 bacteria (with an overall ideal cell 
diameter of approximately 50% the diameter of the tiniest human blood vessels) provide 4.0 to 
4.7pN of thrust force for propulsion (roughly 10 times the value of many other well-known 
flagellated bacteria). Since there are no existing methods or technologies capable of inducing an 
equivalent force on a carrier of appropriate size for traveling inside a tumour’s microvasculature, 
live microorganisms are considered as a viable option. Many of the parameters in a tumour 
microenvironment, such as malformed angiogenesis capillaries, heterogeneous blood flow, and 
high interstitial pressure, hinder the delivery of blood-borne drugs to the affected area. Active 
motility might prove to be helpful in bypassing these limitations and may facilitate the uniform 
distribution of the drug in the targeted area. 
An MTB navigation technique that allows targeting without prior knowledge of the exact 
architecture of the vessels network has been developed. This navigation technique exploits both 
the ability of the MTB to swim following an imposed magnetic field and their random, 
continuous motion at low magnetic fields. Firstly, a focused magnetic field on the target sets the 
overall direction of the bacteria. Then, as the bacteria approach the targeted zone, the intensity of 
the magnetic field is decreased, which allows better bacteria repartition by exploiting their free 
motion. An additional approach that enhances MTB targeting relies on modulating the magnetic 
field direction in time, while keeping the magnetic field lines pointed toward the target. 
Navigation experiments in complex micro-channel networks highlight this process, where the 
successful targeting of bacteria is demonstrated when an appropriate magnetic field algorithm is 
applied, especially when it takes into account the nature of the channel network. Tridimensional 
control and navigation of MTB is also possible with the same technique through proper powering 
of the magnetic coils. In fact, by controlling their magnetic environment, it is possible to form a 
swarm of MTB, control its size and position within a given volume using a computer program. 
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MTB respond to magnetotaxis-based directional control since each cell contains internal 
structures known as magnetosomes. In the case of the MC-1 cells, these structures are composed 
of magnetite (Fe3O4) nanoparticles arranged in a chain that acts similarly to a magnetic nano-
compass. The magnetosomes embedded in each MTB can be used to track the displacement of 
these bacteria using a Magnetic Resonance Imaging (MRI) system. These magnetosomes disturb 
the local magnetic field and affect the T1 and T2-relaxation times during MRI. Magnetic 
Resonance (MR) T1- weighted and T2-weighted images as well as T2-relaxivity of MTB are 
studied in order to validate the possibility of monitoring MTB drug delivery operations using a 
clinical MR scanner. It is found that MC-1 MTB affect the T2-relaxation much more than the T1-
relaxation rate and can be thought of as a negative contrast agent. The signal decay in the T2-
weighted images is found to change proportionally to the bacterial concentration. A minimum 
concentration of 2.2×107 cells/mL can be detected with a standard 1.5Tesla clinical MR system 
using a T2-weigthed image. Furthermore, when the influence of the magnetosome’s chain, the 
motility, and the bacterial cell of MC-1 MTB on the MRI contrast were studied, it was found that 
nanoparticles synthesized by MC-1 MTB were the predominant source of contrast in MRI.  
In vivo studies, invastigating the ability of MC-1 MTB to reach the tumour, revealed the presence 
of these bacteria in the necrotic zone of solid tumours. The application of a magnetic field 
focused on the target, using a special magnetic system that was designed and built especially for 
these in vivo experiments, helped the accumulation of the bacteria in the tumour. In this paper we 
report on average, twice the number of bacteria found in the tumour when a magnetic field was 
applied using the 3D magnetic coils system over passive transport with the blood flow in the 
absence of any magnetic field. A second experience based on the comparison of tumours 
implanted in the same animal reported 10 times more bacteria in the targeted over the non-
targeted tumour, which may suggest that the applied magnetic field may also be used to avoid a 
specific zone in the body.  
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RÉSUMÉ 
Le cancer constitue la première cause de mortalité au Québec, avec 20,000 décès estimés par 
année. Parmi tous les patients atteints du cancer, une grande proportion pourrait profiter de 
l’avancement technologique en ce qui concerne le transport de médicaments. En effet, l’un des 
meilleurs moyens d’augmenter l’efficacité d’un médicament contre le cancer, tout en réduisant sa 
toxicité sur les cellules saines, est de le diriger vers la tumeur et de le maintenir à cet endroit 
jusqu’à ce qu’un effet thérapeutique se produise. Le transport ciblé de médicaments vers la 
tumeur peut considérablement améliorer l’efficacité thérapeutique, surtout si le transporteur est 
capable d’atteindre les zones nécrotiques et se répartir uniformément dans la zone à traiter. Les 
bactéries, de par leur motilité, sont d’excellents candidats pour une telle application, surtout 
qu’elles peuvent aussi être facilement fonctionnalisées. Ainsi, la recherche sur le traitement du 
cancer utilisant des bactéries s’est imposée comme une approche prometteuse surtout qu’elle 
pallie à une limitation majeure de la chimiothérapie et de la radiothérapie en permettant le 
traitement des zones anaérobies. 
Alors que des laboratoires à travers le monde tentent de fabriquer des systèmes miniatures en se 
basant sur le modèle bactérien, nous avons opté pour l’utilisation des bactéries qui existent dans 
la nature. Notre stratégie a été de trouver un système biologique ayant les caractéristiques 
essentielles (e.x. diamètre total de moins de deux micromètres, force de poussée de plus de 4 pN, 
etc.) et de concentrer nos efforts à identifier une interface et une méthode permettant son contrôle 
pour des fins de ciblages thérapeutiques dans les lésions tumorales. Nous avons identifié les 
bactéries magnétotactiques de type MC-1 comme le meilleur transporteur potentiel de 
médicaments pour le ciblage du cancer.  
Les MC-1 sont à la fois dirigeables par champs magnétiques et anaérobies, ce qui leur donne un 
grand avantage par rapport aux bactéries traditionnellement utilisées pour le ciblage du cancer. 
Le ciblage du cancer avec des bactéries exploite le plus souvent l’affinité des bactéries anaérobies 
à la région nécrotique faible en oxygène de la tumeur. Certes, ce ciblage manque de spécificité et 
un des problèmes le plus reconnu est la nécessité d’injecter une forte dose de bactéries pour 
assurer une croissance de celles-ci à l’intérieur de la tumeur. Ceci n’est pas le cas avec les MC-1 
car elles sont à la fois anaérobies et magnétotactiques grâce à une chaîne de nanoparticules 
d’environ 70 nanomètres de diamètre, formant une sorte  de « nano-boussole » magnétique à 
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l’intérieur de chaque bactérie, nous permettant de la diriger. Cette thèse étudie les différentes 
options de controle magnétique, et présente un système de contrôle magnétique programmable 
qui tient en compte d’une utilisation future chez les sujets humains. 
De plus, la même chaîne de nanoparticules responsable du magnétotactisme, nano-cristaux 
d’oxyde de fer, constitue un agent de contraste en imagerie par résonance magnétique (IRM), qui 
est la modalité la plus efficace pour imager certains cancers tel que le cancer colorectal. Les MC-
1, de par la taille de leur magnétosomes, engendrent une perte de cohérence du signal de 
résonance magnétique ce qui se traduit par une perte du signal sur l’image. L’étude des 
mécanismes de contrastes d’échantillons de MTBs révélent que les images en contraste T2 (temps 
de relaxation transversal) sont beaucoup plus affectées que celles en contraste T1 (temps de 
relaxation longitudinal) par la présence des MC-1. La quantité minimale qui peut être détectée 
avec un système standard d’IRM de 1.5Tesla est de 2.2×107 MC-1/mL utilisant un contraste T2.  
Nous avons aussi réalisé des expériences in vivo sur des souris porteuses de tumeurs afin de 
démontrer la capacité de transporter les MC-1 jusqu’à la tumeur. Les bactéries se sont retrouvées 
en grande quantité dans la partie nécrotique des tumeurs suite à une injection intraveineuse. 
L'application d'un champ magnétique focalisé sur la cible, en utilisant un système magnétique 
conçu et construit spécialement pour ces expériences in vivo, a permis d’accumuler les bactéries 
dans la tumeur. Dans cette thèse nous constatons, en moyenne, deux fois le nombre de bactéries 
quand un champ magnétique a été appliqué en utilisant un système de bobines 3D par rapport au 
transport passif avec le flux sanguin en l'absence de tout champ magnétique. Une deuxième 
expérience basée sur la comparaison de tumeurs implantées chez le même animal dévoile 10 fois 
plus de bactéries présentes dans la zone ciblée par rapport à celle non-ciblées, ce qui peut 
suggérer que le champ magnétique peut également être utilisé pour éviter une zone spécifique 
dans le corps, augmentant ainsi la specificité du traitement. Nous avons utilisé deux différents 
montages magnétiques pour le guidage des bactéries. Le premier montage, constitué 
principalement d’un électroaimant alimenté par une source de tension, est adéquat pour les 
tumeurs superficielles et accessibles. Le deuxième montage, constitué d’un ensemble de bobines 
tridimensionnel,  permet un ciblage dans des sites profonds et inaccessibles permettant ainsi 
d’étendre l’application de l’utilisation des MC-1 pour le ciblage à plusieurs types de cancers dans 
le futur. 
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INTRODUCTION 
 
Over the past two decades we have seen significant improvements in progression-free survival 
and reductions in morbidity for a number of cancer treatments, driven by the advent of 
biologically targeted therapies and more effective treatments. Many of these newer agents (e.g. 
Bevacizumab, Trastuzumab) actually sensitize tumours to the mainstay of anticancer therapy, 
cytotoxic chemotherapy. The latter is limited by significant acute and cumulative toxicities, such 
as myelosuppression and cardiac toxicity. While metastatic cancers most often require systemic 
therapy, there are specific contexts in which more effective localized therapy would have major 
impact on both quality of life and survival, including rectal and colorectal cancers, hepatocellular 
cancer, liver metastases from colorectal cancer and glioblastoma. We propose to use MC-1 
magnetotactic bacteria (MTB) as a drug delivery system for solid tumours. MC-1 MTB use 
flagella for propulsion, while their swimming direction can be controlled by computer using an 
external directional magnetic field. This field induces a torque on a chain of nanoparticles that are 
naturally synthesized in the cell during cultivation. Like a compass needle, the swimming 
direction of the MTB is influenced through magnetotaxis.  Furthermore, the MC-1 MTB 
spherical cells have a diameter of approximately 2µm, ideal for navigation in the smallest blood 
vessels, using an average swimming speed exceeding 200µm·s-1. Although the final aim of this 
research is to treat cancer, the bacteria used are not drug-loaded yet and do not produce any 
therapeutic effect. We are developing the concept of guiding the bacteria to solid tumours, and 
we are confident that once the proof of concept is achieved, following research projects will 
transform the bacteria for a therapeutic effect to take place. 
The research hypotheses were as follows: 
Hypothesis 1: It is possible to control the motion of a MC-1 MTB swarm in a tridimenstional 
space under computer control. 
Hypothesis 2: MC-1 MTB cause a significant magnetic resonance signal distortion making their 
targeting possible using clinical MRI systems. 
Hypothesis 3: MC-1 MTB are able to reach the necrotic region of solid tumours. 
  2 
 
We will address three main objectives in this thesis: Objective 1: development of a 
programmable MC-1 MTB magnetic control system. This system has to be designed for a 
human patient even though there are no planned human trials. Objective 2: characterization of 
the contrast caused by the MC-1 MTB on magnetic resonance images. The magnetic control 
system combined with the magnetic resonance imaging will form the future platform for MTB 
guidance. Objective 3: assess and quantify the MC-1 distribution in tumour xenografts and 
evaluate the magnetic guidance advantage over passive targeting. 
Chapter 2 of this thesis studies the hydrodynamics of the MC-1 magnetotactic bacteria in high 
magnetic fields. It elaborates the influence of the magnetic torque on the overall motion of the 
bacteria and the consequences following application of a high magnetic field on a bacterial 
sample such the one found in MRI systems. Increasing the magnetic field leads to a decrease in 
speed of the MTB. During these observations, the magnetic field up to 1.27Tesla was used, 
which is quite similar to the one found in most MRI systems (1.5Tesla). Most importantly, MTB 
show a change in polarity when the field is released; for example, if a sample of 100% north-
seeking bacteria is submitted to a 1 Tesla field, the MTB will be divided into 50% north seeking 
and 50% south seeking bacteria once the field is released. This observation greatly impacts the 
targeting method as we have suggested at the beginning of the project to use the MRI image as a 
feedback to correct the magnetic field used to control the bacteria. In fact, we can conclude that 
doing this will change the bacteria’s behavior, which will have a negative impact on 
controllability during in vivo drug delivery applications. A mathematical model describing the 
interaction between the magnetosome chain and the magnetic field and how it affects motion is 
presented along with a an explanation on what causes the bacteria to change polarity when they 
hit an obstacle.  
Chapter 3 covers the different MTB control techniques that are suitable for in vivo drug delivery 
applications. After several iterations, designs and much experimentation, we found that the coil 
structure providing the best results for MTB navigation was a mix of 3-axis Helmholtz coils and 
3-axis Maxwell coils. The Maxwell configuration traps the MTB that follow the magnetic field 
lines in the center of the coils. Controlling the motion of the bacteria then becomes possible using 
the computer-controlled Helmholtz coils. The current flowing in the Helmholtz coils and the 
position of the zero fields generated from the Maxwell coils are linearly related. 
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 In chapter 4, we characterize the swimming of MTB in vitro by mimicking different situations 
they could encounter in an in vivo environment. The goal was to be able to predict the MTB 
behavior in a complex microvasculature and to choose the correct magnetic field algorithm to 
optimize targeting. In fact, as the MTB follow the magnetic field, they could easily get stuck on 
obstacles, especially in very complex capillary networks such as the tumour angiogenesis. 
Consequently, changing the direction of the field is necessary to guide the bacteria. The problem 
is a lack of visual information on the route and obstacles that the bacteria face. 
Since we lack this information, we must achieve blind control knowing only the starting position 
of the bacteria (the injection site) and their final destination (the center of the tumour). As a 
simple example to help understand the problem and the way we propose to solve it, we used a 
microchannel design consisting of multiple U-channel shapes. The bacteria were injected into 
two tanks connected to the network through a small capillary. The magnetic field was set to a 
target location. We measured the number of bacteria that reached the target as time passed.  
We show in this paper that a magnetic field algorithm is very important in order to navigate the 
bacteria accurately and that it can be generalized to complex geometries. Taking into account the 
geometry of the channels, the bacteria’s speeds and behavior for a given magnetic field, we can 
optimize targeting with the appropriate magnetic field. Modeling and simulation can play an 
important role in this case. In fact, using the typical architecture of angiogenesis found in 
scientific literature in addition to the characterization of bacteria when submitted to different 
environmental parameters, we can predict and engineer a magnetic field algorithm that would 
optimize targeting. The direction, intensity and duration of the magnetic field are the three 
parameters to consider for MTB guidance. Changing the direction of the magnetic field allows 
the MTB to bypass obstacles while modulation of its intensity will give more or less freedom to 
the MTB to deviate depending on oxygen or other physical entities.  
The paper presented in chapter 5 extends the usage of the magnetic control method presented in 
chapter 5 to a three-dimensional space and presents the required time multiplexing of coil 
powering in order to achieve bacterial swarm control in 3D. The notion of a magnetic monopole 
does not exist in nature and it is impossible to reproduce in laboratory. In fact, the magnetic field 
that converges in a two-dimensional space exits from the third dimension. We propose in this 
paper a method that allows us to retain a swarm of bacteria in a target location. 
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Chapter 6 presents the in vivo results of MTB delivered to a tumour xenograft implanted on a 
mouse. Two different magnetic setups were used for the delivery of MTB to the tumour 
following their intravenous injection. The first setup consists of an electromagnet placed as near 
as possible to the tumour, while the second involves the use of the tridimensional-coil system 
described in chapters 4 and 5. Since MTB have a life span of 30-45 minutes at body temperature, 
the duration of the experiment was set to 30 minutes during which the magnetic field was applied 
to the tumour. Following the experiment, the animal was euthanized and the tumour extracted for 
analysis. Histochemical staining allowed identification of the bacteria on the histology slide. 
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CHAPTER 1 LITERATURE REVIEW 
This literature review is comprised of four parts. The first part covers the main cancer therapy 
methods as well as the major physiological barriers that drugs encounter on their way to targeted 
tissues. The goal of the first part of this review is to bring to the reader’s attention the importance 
of developing a tool that deliver the active drug directly to tumours. The second part discusses 
methods of delivery, namely the magnetic drug targeting approach and the Magnetic Resonance 
Propulsion (MRP) method that was first proposed and developed by the NanoRobotics laboratory 
of the Ecole Polytechnique de Montreal. The third part covers the use of bacteria in cancer 
treatment and focuses on their application clinical applications. Finally, the last part of the review 
presents the MC-1 magnetotactic bacteria (MTB) and discusses particularities of the MTB that 
are accessible in the literature. 
1.1 Cancer Therapy Approach 
Cancer, as well as the therapy undergone following its diagnosis, is classified depending on 
where it develops in the body. For example, patients with colorectal cancer1 will undergo 
integrated surgery and chemotherapy whereas in the case of patients with rectal cancer, additional 
radiation therapy is used. On the other hand, hepatocellular carcinoma2 (HCC) requires resection, 
liver transplantation, and percutaneous ablation (percutaneous ethanol injection (PEI) and 
radiofrequency (RF)) that can only be used on 30-40% of the patients. Meanwhile, 
chemoembolization is the only alternative therapeutic strategy capable of improving survival for 
the majority of patients. Chemoembolization combines arterial administration of drugs with a 
form of arterial occlusion in the liver by an embolizing agent. Systemic therapies, which affect 
the entire body, are used for the treatment of almost all type of cancer. 
                                                
1 Colorectal cancer is the third most prevalent malignancy worldwide and the second leading cause of cancer death in 
Canada based on Canadian Cancer Statistics 2009. 
2 Liver cancer is a leading cause of cancer deaths worldwide based on The American Cancer Society.  
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1.1.1 Systemic therapies 
The most common systemic therapies are radiotherapy, chemotherapy, immunotherapy, and gene 
therapy. Radiotherapy involves irradiation of the tumour by ionization radiation that damages 
the DNA of cancerous cells.  It is used for patients who are not permissible for surgery, or as a 
complementary treatment. The source of radiation can be external or internal, which mainly 
depends on the affected organ. Image-guided radiotherapy accounts for the body motion, such as 
respiration and internal organs motion, through the use of advanced imaging modalities. The 
efficiency of radiotherapy is however hindered by the hypoxic nature of the center of solid 
tumours that poses a limitation since the cells in this region are 2 to 3 times more resistant to 
radiation than normal cells [1, 2]. This region of the tumour also decreases the efficacy of 
Chemotherapy, which relies on systemic blood circulation to transport drugs. Chemotherapy 
acts by killing rapidly dividing cells such cancerous ones, and as a matter of fact, quiescent cells, 
which are far from the vasculature, are hardly affected [3]. In order to reduce its side effects, the 
active agent is encapsulated inside particles that attach to certain proteins present on cancerous 
cells and are subsequently actively targeted at tumours [4]. Active targeting is not to be confused 
with direct delivery, which encompasses methods that physically transport the active agent to the 
tumour. Immunotherapy enhances the way the immune system deals with cancerous cells by 
inducing a response against the antigen they express [5]. It consists of injecting lymphocyte cells 
that are “trained” to recognize and destroy specific cancer cells.  Gene therapy uses a vector, 
usually a virus, to transport and inject healthy human genes inside cancerous cells. The short 
circulation time of vectors as well as their toxicity, immune system responses, gene control and 
targeting issues all prevent successful medical application of this technique [6]. The success of 
the techniques mentioned above depends on the efficacy of the active agent in killing cancerous 
cells as well as the quantity that reaches the tumour. The injected dose is limited by the tolerance 
of the body since systemic therapies affect cancerous cells as well as healthy cells [7, 8]. 
Moreover, tumours induce many physiological barriers that hinder the drugs from reaching the 
target. 
1.1.2 Physiological barriers 
The systemic therapies described in the previous section rely on transporting particles, molecules 
or cells to the tumour. For the therapy to be successful, the active agent must reach the tumour in 
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sufficient quantity. First, the active agent has to reach the main blood vessels that lead to the 
tumour; second, it must extravagate in the interstitial space of the tumour, and then migrate so as 
to be in direct contact with the cancerous cells [9-15]. The heterogeneous blood flow of the 
tumour and the high interstitial pressure are the major obstacles that drugs need to surmount to 
reach the target [16-20]. 
1.1.2.1 Tumour blood supply and transvascular transportation in tumours 
The rapid growth of the tumour generates a lack of oxygen and nutrients and triggers the creation 
of new blood vessels, which is known as angiogenesis [21, 22]. Blood vessels thus created are 
different from healthy ones, and are characterised by leakiness, ill formation, and 
inhomogeneities [23-25]. In fact, large pores exist in tumour blood vessels [26]. The pore size 
depends on the tumour itself as well as nearby organs [14, 15, 19, 20, 24], it can range from a 
nanometer, as is the case with human glioblastoma (HGL21) transplanted in the cranial windows 
of a mouse [27], to 2000nm for the mammary adenocarcinoma of a mouse (MCalV) transplanted 
into the dorsal skinfold chamber [28]. Moreover, tumour angiogenesis blood vessels have dead 
ends, ramifications and an irregular size [11, 12, 16-18]. Heterogeneities characterise 
transvascular transport in tumours, as shown experimentally in [15], where fluorescent liposomes 
that were injected in tumour-bearing mice accumulated in some regions of the tumours but not in 
others. These characteristic particularities of tumour blood supply dictate the way drug molecules 
reach the tumour cells. In addition, systemic therapies have different therapeutic effects 
depending on the perfusion of the tumour. In fact, there are four distinct regions where the 
treatment is perceived differently as depicted by Figure 1.1. The first region is a hypoxic necrotic 
one, the second is a semi-necrotic region, the third is a stabilized microcirculation region, and the 
fourth is an advancing front [10, 29]. 
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Figure 1.1. Differences between normal vasculature and one found in tumours. While normal vessels are regular 
and supply a homogenous blood flow to surrounding tissues, tumour angiogenesis blood vessels have dead ends, 
ramifications and an irregular size. Four distinct regions are noticeable where the treatment is perceived 
differently. The first region is a hypoxic necrotic one, the second is a semi-necrotic region, the third is a stabilized 
microcirculation region, and the fourth is an advancing front. Adapted from [30] 
 
1.1.2.2 Interstitial transport in tumours 
Molecules or particles that successfully cross the vascular wall will encounter a second major 
obstacle before reaching cancerous cells. Transport through interstitial space poses a real 
challenge for passive particles because of the high interstitial pressure inside the tumour and the 
lack of functional lymphatic vessels [31]. However, when the interstitial space of tumours is 
evaluated, it is found that it is much larger than those found in normal tissue [32, 33]. While this 
observation might suggest that transporting molecules and particles should be easier in tumour 
tissue than in normal tissue, experimental data shows the opposite. In fact, the interstitial 
hydrostatic pressure is high in the center of the tumour and low in the periphery. Therefore, 
interstitial fluid motion is expected to move from the center of the tumour to the periphery. 
Various studies show that 1-14% of plasma entering the tumour leaves through the periphery 
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[34]. The outward fluid velocity resulting from this leakage is estimated to be 0.1-0.2 µm/s at the 
periphery of 1 cm of tissue-isolated tumour [9]. Thus, particles or molecules must counter this 
fluid motion in order to reach the interior of the tumour. 
Diffusion and convection govern passive transportation of molecules in the interstitial space. 
Furthermore, because of micro and macroscopic heterogeneities in tumours, the magnitude of 
these two parameters varies inside the same tumour and over time as well as from one tumour to 
another [35]. Active transport, such as the use of micro-engineered systems, magnetic particles 
steered by magnetic fields, or bacteria may enhance the transportation of drugs in transvascular 
and interstitial spaces, as will be discussed in the next section. 
1.2 Direct drug delivery to tumours  
Transportation of untethered microcarriers bearing therapeutic agents through the vascular 
network of a human body to a target requires an appropriate propulsion and steering system. The 
development of such propulsion and steering system can be a real technical challenge especially 
when the dimensions of these microcarriers must be reduced to a diameter of approximately 2µm 
to allow them to operate efficiently in the narrowest blood vessels of the microvasculature. An 
entirely synthetic approach that does not rely on an external source of induced propulsion force is 
beyond the limit of current technology. In fact, approaches that do rely on an external source for 
propulsion are still facing many technological challenges when designed to operate in the human 
microvascular networks. The major limitation consists of difficulties in miniaturising the power 
source that allows efficient autonomy of the microcarrier. 
1.2.1 Synthetic systems 
Flagellae and cilia, nanomotor-like mechanisms by which most microorganisms move, have 
inspired researchers in the design of modern engineering tools. Artificial Bacterial Flagellum 
(ABF) made from a helical tail, resembling a natural flagellum, and a soft-magnetic material head 
was fabricated in [36], based on a principle that was theoretically described in [37]. Under the 
action of an alternating magnetic field, the ABF was successful in reproducing the bacterial 
motion using a synthetic system [38, 39] as depicted by Figure 1.2. However, profiting from the 
existing flagella of microorganisms such as bacteria appeared more advantageous [40-44]. 
Successful on/off motion control of the bacteria by adjusting the chemical composition of their 
  10 
 
medium was demonstrated in [45]. In addition, bacteria have shown to possess sufficient thrust 
force to move micro-objects from one location to another [46], and to build more complex 
structures under the conjoint action of a swarm of microorganisms [47].  
 
Figure 1.2. A computer controlled swarm of Magnetotactic bacteria was able to build a tiny pyramid made of SU-5 
material blocks as depicted in A [47]. In B a scheme of a hybrid system made from synthetic material and propelled 
by the conjoint action of several bacteria attached to its end [42]. Scheme of a bacterium showing its body and an 
attached helical structure called flagella responsible of the bacterial motion through its spinning. The bacterial 
motion was reproduced by a synthetic system made from soft magnetic material head and a helical tail as shown in D 
[36]. Motion of this artificial flagella is granted through application of an alternating magnetic field generating a 
torque on the structure’s magnetic head as depicted in E [36]. 
1.2.2 Magnetic drug targeting 
Magnetic Drug Targeting (MDT) is a technique that magnetically concentrates drugs at the 
tumour site in order to reduce secondary toxicity effects that follow common therapies in cancer 
treatment [48-52].  Currently, MDT consists of loading drugs into magnetic particles that carry 
this complex in the vicinity of a tumour using an external applied magnetic gradient as described 
by the Figure 1.3. Moreover, lack of navigational control when combined with complex 
A C 
B 
D 
E 
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microvascular networks near a tumour contributes further in lowering the efficacy of such 
targeting. 
Present implementations for magnetic targeting of tumours rely on an external permanent or an 
electro-magnet located near and above the tumour. In this method, a catheter is typically used to 
release the magnetic nanoparticles as close as possible to the target. However, due to higher field 
intensity towards the external magnet [53], targeting is mostly restricted to superficial tumours 
near the skin. Because of higher magnetic gradient intensity towards the external magnet, 
targeting efficacy is higher for tumours located near the magnet and decreases substantially when 
the tumour is located deeper in the body.  
Therefore, as the targets get deeper in the body, significant reduction of targeting efficacy is 
anticipated with this technique. Furthermore, this approach relies on trapping the particles 
without any further navigation or trajectory control over pre-planned pathways towards the 
tumour; thus, the distance between the nanoparticles releasing site and the tumour significantly 
affects targeting effectiveness. The dimensions and the technology of the available 
catheterization will always limit the efficacy of this technique to reach a desired site in the 
complex microvasculature. Deep organ targeting has been improved through the use of magnet 
tipped catheter, magnetic needles, wires or stents [48, 54-56], but still, the non-linear geometry of 
the induced field and the resulting distribution of the particles remain uncontrolled. 
When tumours near the surface are considered, such as head, neck and skin carcinomas, 
experimental data showed complete remission of the tumour after one treatment using magnetic 
particles. This significant achievement lead to better efficacy with only one-fifth the medication 
that would otherwise conventionally be needed. Combining MDT with hyperthermia is yet 
another approach to enhance efficacy of a well-established tumour treatment. Involvement of big 
companies such Siemens provide a positive outlook for the clinical future of this technique. 
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Figure 1.3. Principles of the magnetic drug targeting method. An active anticancer agent is encapsulated with a 
magnetic material forming a magnetoliposomes. Following an intravenous injection, retention of the magnetic 
particles that contain the drugs is achieved through the application of a strong magnetic field generated by an 
external source [57]. 
 
1.2.3 Magnetic Resonance Propulsion (MRP) 
In order to improve targeting efficacy for tumours located deeper in the body, a new method has 
been proposed. This method relies on an induced propulsion force on magnetic materials (with 
sufficient magnetization saturation) generated by the three orthogonal coils used for image 
encoding in conventional clinical Magnetic Resonance Imaging (MRI) systems. [58-64] Using 
the tracking information provided by the imaging modality of the MRI, a closed-loop computer 
controlled displacement of a ferromagnetic bead along a pre-planned pathway in the vasculature 
of a living animal was demonstrated. The experiment was conducted in the carotid artery of a 
living swine and the results illustrated that this technology was able to adapt the navigation of 
magnetic microparticles through the microvasculature for future therapeutic applications beyond 
the limits of modern catheterization. This experiment also ensured that using MRI as an imaging 
modality would not only be advantageous for the purpose of tracking of the magnetic 
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microparticles, but also for real-time monitoring of therapeutic efficiency during such 
interventions [61]. 
 
Figure 1.4. Successful MRI-based navigation, targeting, and controlled release of a cancer drug in a pre-defined lobe 
in the liver of a live rabbit [64]. 
Inducing sufficient force on nanoparticles would require magnetic gradients with amplitudes that 
are beyond today’s technological advances when operating at the human scale. This is due in 
great part to the very small volume of the magnetic materials involved. Even if such high 
amplitude gradient field was achievable, there are physiological limitations to the gradient field 
amplitude that have previously been pointed out. One possible solution when operating in the 
microvasculature is to encapsulate such magnetic nanoparticles with therapeutic agents within 
polymeric microcarriers [64] as shown in Figure 1.4. With this approach, a higher effective volume 
of magnetic material can be achieved while retaining the advantages offered by the properties of 
magnetic nanoparticles for MR-target applications. However, tumour lesions are typically 
accessible by transiting through anarchic arteriocapillar networks stimulated by tumour 
angiogenesis. These capillaries are as small as 4-5µm in diameter. As such, this environment 
restricts the overall maximum diameter of each magnetic microcarrier for efficient navigation to 
approximately 2µm. Although at such a scale, the blood flow would typically be used for 
propulsion, sufficient magnetic gradient must still be generated to steer such microcarriers 
efficiently, especially at vessel bifurcations. Preliminary studies showed that additional gradient 
steering coils could provide maximum gradients sufficient for larger microcarriers used for target 
chemo-embolization but may prove to be insufficient for enhanced targeting inside a tumour. 
One approach proposed by our group is to eliminate the need for such gradient coils when 
operating in the microvasculature and to replace it by the propulsion force provided by flagellated 
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bacteria. Since steering control is also required for target interventions, special types of cells 
referred to as Magnetotactic Bacteria (MTB) are considered by our group for such applications. 
1.3 Bacterial cancer therapy 
Bacteria that are present in the human body outnumber human cells by a factor of 10 to 1 [65]. 
Relying on complex mechanisms for their motion, sensory apparatus and communication, they 
play important roles in many aspects of the body’s operation. Ever since a patient accidentally 
infected by bacteria recovered from cancer in 1891 [66], many researchers have focused on the 
use of bacteria as a potential treatment for cancer [6, 67-74]. The phenomenon by which the 
bacteria helped the patient to recover from cancer remains unknown, though many researchers 
believe that their ability to proliferate in the center of a solid tumour, and their production of 
toxins figure as key factors. Among the tremendous number of bacteria available in nature, the 
anaerobic ones (i.e. bacteria that live in the absence of oxygen) have been the primary 
consideration for most researchers that have tried to reproduce the accidental success witnessed 
by Dr. Coley [66, 73]. Figure 1.5 shows an example of an application for the bacterial cancer 
therapy. 
1.3.1 Principle of bacterial therapy 
Bacteria are believed to be more specific when targeting hypoxic regions of the body that are 
characteristic of solid tumours [68]. The commonly used bacteria belong to the Clostridia, 
Salmonella and Bifidobacterium strains [75]. They can be genetically modified to express a 
certain gene that can have an antitumour effect or supress certain genes to make the bacteria 
better tolerated by the body. The therapeutic effects come from the bacteria thriving from 
consuming necrotic cancerous tissue, or through products of bacterial activity such as endotoxins, 
which can be used for tumour destruction. Bacteria can also be used as delivery agents for 
anticancer drugs, and as vectors for gene therapy. 
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Figure 1.5. Anaerobe bacteria colonize the necrotic central regions of solid tumours following an intravenous 
injection. The bacteria can be engineered to produce toxins that cause the death of cancer cells once in a poorly 
vascularized zone [67]. 
 
1.3.2 Tumour-colonizing bacteria 
It was found through animal model experiments that, following an intravenous injection, 
anaerobic bacteria found an appropriate environment for their proliferation in the hypoxic region 
of solid tumours as shown in an histology slide in Figure 1.6. The presence of pathogenic 
anaerobic clostridia species resulted even in tumour regression, but caused a severe toxicity, 
which resulted in either death or illness of the host animal [76, 77]. Non-pathogenic strains of 
Clostridium were also able to colonize the hypoxic zone of solid tumours, yet they did not cause 
tumour regression as the pathogenic strain did [78]. An attenuated strain, the C. novyi-NT, which 
was obtained after deleting gene coding for lethal toxin, caused tumour regression, but the 
  16 
 
quantity that was necessary for a therapeutic effect to take place still produced toxicity. However, 
when the bacteria were administered in combination with chemotherapy, extensive hemorrhagic 
necrosis of the tumours resulted in significant and prolonged antitumour effects, which is best 
known as combination bacteriolytic therapy (COBALT) [69]. 
1.3.3 Combination bacteriolytic therapy (COBALT) 
There are two main motivations behind the combination of bacteria therapy and existing 
treatment. Firstly, the bacteria are unable to consume living cancerous cells at the tumour. So, 
while the bacteria consume the tumour from the inside out, a chemotherapeutic agent would treat 
cancer cells in the well-perfused periphery that is accessible through the vasculature region. 
Therefore, combining both techniques could bypass major limitations in bacterial therapy and 
chemotherapy, which are the inability of chemotherapy to reach the necrotic zone and the 
inability of bacteria to proliferate in the wee-perfused tumour region. Furthermore, C. novyi has 
been tested to make the necrotic region of the tumour accessible to drug, or to enhance the release 
of liposome-encapsulated drugs [79]. Salmonella typhimurium was also investigated through the 
VNP20009 strain after deletion of two genes encoding endotoxins. Since the VNP20009 is a 
facultative anaerobe, it was successful in targeting small tumours that lacked a necrotic zone. Its 
specificity in growing in tumours was established through making its growth depending on an 
external source of purine, which is a compound that is available in tumours and not in organs 
such as liver or spleen. Not only has chemotherapy been combined with bacterial therapy, C. 
novyi has also been investigated in conjunction with radiotherapy in experimental tumour models 
[68, 80]. Phase I clinical trials in cancer patients has been conducted for the VNP20009 [81]. It 
has been demonstrated that the VNP20009 strain of Salmonella typhimurium can be safely 
administered to patients. At the highest tolerated dose, some tumour colonization was observed, 
yet no antitumour effects were seen.   
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Figure 1.6. Histology slide showing the presence of Salmonella inside a solid tumour [74]. 
 
1.3.4 Problems associated with bacterial therapy 
The risk of infection and the mitigated success have made many researchers concentrate their 
work on using the toxins produced by these bacteria rather than using live cells for treatment. 
Even though the preferential replication and accumulation of many bacteria in tumours was 
proven since then, bacteria cancer therapy faces many challenges before it becomes clinically 
effective. The first major limitation is the necessary high dose required to induce a significant 
therapeutic effect, which is most of the time associated to severe toxicities. The inefficiency of 
bacteria to target small tumours, where a hypoxic zone is not formed yet, constitutes the second 
major limitation. In addition, combining bacterial therapy with other conventional methods, such 
as chemotherapy or radiotherapy, is mandatory in most cases for complete tumour consumption. 
These bacteria could reach tumoural lesions by means that are not compatible with electronic 
computer such as chemotaxis. Although there are efforts to control the motion of chemotaxis-
based bacteria in an aqueous medium [45], the use of bacteria being influenced by magnetotaxis 
is more appropriate and efficient for computer-based navigation such as target interventions in 
microvasculature [82-84]. Furthermore, the use of MTB can not only enhance targeting through 
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flagellated propulsion and directional control from an external system, but can also be tracked for 
feedback control by MRI due to the chain of magnetosomes in the cell that causes a local field 
heterogeneity detectable by MRI.  
1.4 Magnetotactic bacteria 
1.4.1 General description 
A photograph of a MC-1 MTB is depicted Figure 1.7. From an engineering point-of-view, this 
bacterium can be considered as a micro-robot possessing an efficient molecular motor, sensory 
and actuation capabilities as well as an embedded remote control interface. MC-1 is a cocci 
bacterium and measures approximately 2 micrometers (µm) in diameter. Each cell has two 
flagella providing a thrust force exceeding 4 picoNewtons (pN). This value is relatively high 
compared to other flagellated bacteria with a typical thrust force in the range of 0.3-0.5pN. This 
allows the MC-1 bacteria to swim in water at room temperature and without load at speeds often 
exceeding 200µm/s. This is a very high speed when we know that the swimming speeds of most 
flagellated bacteria in the same conditions are ~30µm/s. 
 
Figure 1.7. Electron scan microscopy images of MC-1 magnetotactic bacteria showing the round shaped cell with its 
internal organelle magnetosomes assembled into a chain. The MC-1 cells possess also two bundle sets of flagella. 
The magnetosome size range between 30-80nm [44]. 
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Unlike most bacteria that base their motility and detection of nutrients on chemotaxis, the 
direction of displacement of MTB, although also influenced by chemotaxis and aerotaxis, is also 
influenced by magnetotaxis through their chain of magnetosomes, which are membrane-based 
nanoparticles of a magnetic iron [84]. When subjected to a magnetic field slightly higher than the 
earth’s magnetic field of 0.5 Gauss, the directional motions of these MTB become mainly 
influenced by magnetotaxis and therefore fully controllable by electronics and computers [44, 
46]. 
1.4.2 Choice of MTB 
Although several types of MTB exist and can be found all over the world [85-88], the selection 
process for the type of MTB to be used as a drug delivery vehicle is still constrained since only a 
few types can be cultured in artificial or laboratory conditions. Most cultured strains belong to the 
genus Magnetospirillum (M.) and include species such as M. magnetotactium strain MS-1 [89], 
M. magneticum strain AMB-1 [87], M. gryphiswaldense [85]; the marine vibrios strains MV-1 
and MV-2 [88]; a marine coccus, strain MC-1 [46]; a marine spirillum strain MMS-1 (formerly 
MV-4) [86]; and sulfate-reducing rod-shaped MTB known as Defulfovibrio magneticus strain 
RS-1 [88]. 
 
Table 1.1. Summary characteristics of some MTB 
MTB  NAME CELL MORPHOLOGY 
Mean Speed 
(µm·s-1) 
WIDTH (OR 
DIAMETER) 
(µm) 
LENGTH 
(µm) 
MC-1 [44] Coccoid 200 2 - 
Magnetospirillum gryphiswaldense [85] Helical 50 0.2–0.7 1-20 
AMB-1 [86] Helical 49 0.5 3-10 
MV-1 and MV-2 [87] Vibroid to Helical -* 0.2–0.5 1-5 
MMP (Many celled Magnetotactic 
bacteria)[87] 
Sphere (a cluster 
of 10-30 Coccoid 
cells) 
105 3-12 - 
Magnetobacterium bavaricum [87] Rod-shaped 40 1–1.5 6–9 
RS-1[87] Helical to Rod-shaped -
* 0.9–1.5 3-5 
Magnetospirillum magnetotacticum 
(MMS–1) [88] Spirillum 40 0.5 5 
-*Missng data 
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For drug delivery applications, higher swimming speeds typically become one of the key factors 
for selecting the right MTB. In general, the magnetotactic spirilla are at the slower end 
(<100µm/s) while the magnetotactic cocci are at the faster end at >100µm/s. As such, the MC-1 
strain seems to be a good choice and has been selected in this particular study. If the size of the 
MTB is an important aspect to consider, the MV-4 bacterium is the smallest with a length of 
~0.5µm compared to ~2µm for the MC-1, but the choice for a smaller cell is done at the cost of 
slower swimming speeds (range of ~30-80µm/s). Both previous types have two bundles of 
flagella on one side of the cell and they are classified as polar MTB. Polar MTB swim 
persistently in one direction along the magnetic field. Polar MTB unlike axial MTB are generally 
more suitable for drug delivery applications since they are usually more predictable when 
controlling their swimming directions. For instance, some cells have two bundles of flagella on 
both ends. These MTB swim in both north and south directions with unpredictable reversals. 
Generally, the proportion of polar bacteria swimming in each direction is same, while for MC-1 
cells the proportion is 80%-20%. 
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CHAPTER 2 DYNAMICS OF MC-1 MAGNETOTACTIC BACTERIA 
AT HIGH MAGNETIC FIELDS 
2.1 Introduction 
Applications involving Magnetotactic bacteria are continually increasing since their discovery by 
Blackmore in 1975 [82]. Besides being the simplest microorganisms known that uses the Earth’s 
magnetic field for guidance, their swimming direction can be controlled through computer 
interface using magnetic coils or magnets [46]. The direction of movement of the bacteria is 
controlled by applying magnetic fields that influence the orientation of a chain of nano-scale 
organelles named magnetosomes. From systems on chips [90], to magnetic resonance contrast 
agents [91], MTB are being integrated in many engineering applications and even investigated as 
a drug-targeting vehicle for cancer treatment [43, 44, 60]. 
Few studies focus on the dynamics of MTB at high magnetic fields. The motion of MTB has 
been studied mostly at relatively low fields, more specifically around the Earth’s 0.5 Gauss 
magnetic field. With the emergence of new applications, such as those involving magnetic 
resonance imaging systems, the MTB are subjected to extremely high fields, equalling 30,000 
times the Earth’s field. The dynamics of MTB at high magnetic fields differs from that at low 
fields. We expect these differences to be caused by the physical interaction of the magnetosome 
chain with the external magnetic field. 
Similar phenomena involving other strains of MTB are reported in the literature, which may be 
caused by the same physical principles than those reported in this paper. The increase in the pitch 
angle of MTB helical motion at high magnetic fields has been observed with uncultivated 
magnetotactic enriched coccus from Lake Miyun near Beijing, China [92]. However, the 
magnetic fields used in [92] to study the helical motion, range from 1 to 15 Gauss while the ones 
used in this paper range from 0 to 600 Gauss. Furthermore, excursions opposite to the magnetic 
field direction after collision with the edge of the water droplet have been observed with a 
Magnetotactic Multicellular Prokaryote (MMP) [93]. Further studies [94] suggested that this 
"ping-pong" motion might result from the magnetoreceptive capability of the MMP since it could 
not be explained by conventional magnetotaxis. MC-1 also exhibits excursions in the direction 
opposite to a high magnetic field followed by a continuous "ping-pong" motion as long as the 
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field remains applied. Contrary to the MMP, and due to the relatively simpler model of the MC-1 
bacteria, an explanation using conventional magnetism is possible especially when using the 
chain of spheres model for polarity reversal [95].  
For the purpose of this paper we used MC-1 MTB that are polar coccus gram negative bacteria 
having one magnetosomes chain made up of 10-15 Fe3O4 nanoparticles. These bacteria move 
using two bundles of flagella located in one extremity of the cell body. The speed of this 
bacterium can reach up to 300µm⋅s-1 making their flagella very effective at low Reynolds number 
flows. Interaction between the magnetosome chain and the external magnetic field is probably the 
cause of the bacteria’s change in motion when the magnetic field is increased, as can be 
demonstrated using a simplified mathematical model based on previous work done by Noguiera 
and Lins De Barros [96]. 
2.2 Materials and Methods 
2.2.1 Bacterial growth and preparation 
Magnetococcus sp. (MC-1) was grown in a chemoheterolithotrophic liquid medium under 
microaerobic conditions. Iron-enrichment of the medium was done using 50µM of ferrous sulfate 
heptahydrate FeSO4⋅7H2O (F8048, Sigma-Aldrich). The bacteria were used at day seven, which 
corresponds to the end of their exponential growth phase. 
2.2.2 Motion observation 
Magnetotactic bacteria motion has been observed under a phase-contrast capable Zeiss optical 
microscope. It was possible to record the helical motion of the MTB by increasing the shutter 
speed of the Sony camera used to transfer video recordings to a computer. Images were 
investigated for the measurement of the helical motion pitch angle !!, the longitudinal speed !! 
and the transverse speed !!" using MATLAB (The MathWorks, Natick, MA). 
2.2.3 Magnetic field 
A 30×15×10mm neodymium (NdFeB) rare earth magnet was used to generate a strong magnetic 
field of 600 Gauss. The drawback associated with the use of a rare earth magnet is that the 
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resulting magnetic field gradient can induce a force on the magnetosome chain. This force is 
given by, 
!!"# =      ! ⋅ ! ! = ! ⋅ ! ⋅ ! ! (2.1) 
where !!"# is the magnetic force ! , ! is the magnetic moment of the ferromagnetic body ! ⋅!! , ! is the magnetization of the material ! ∕! , ! is the volume of the magnetosome 
chain !! , ! is the magnetic ﬁeld ! , and ∇! is the gradient or spatial variation of the 
magnetic ﬁeld ! ∕! . Whether the magnetic gradient field affects the dynamic of magnetotactic 
bacteria or not is unknown, however for the purposes of this paper we discard its influence based 
on the two following assumptions. First, the magnetic force is proportional to the volume of the 
magnetic particle. The MC-1 bacteria are made up of a single magnetosome chain comprised of 
10 to 15 magnetosomes, which have a mean diameter of 50nm as depicted in Figure 2.1. Hence, 
the magnetic force is expected to be quite small, particularly in the case of MC-1 MTB. 
Secondly, the gradient is a spatial variation of the magnetic field. The smaller the field of view, 
the smaller the variation of the magnetic field. 
 
Figure 2.1. Bright-ﬁeld transmission electron micrograph (TEM) of a negatively stained cell of MC-1. The cell 
contains a single chain of magnetosomes and possesses two bundles of ﬂagellae (not visible on the image). There are 
10-15 magnetosomes per bacteria, having an approximate mean size of 50nm. 
2.2.4 Mathematical model 
Noguira and Lins De Barros [96] have developed a mathematical model for the hydrodynamics 
of MTB describing their motion with six degrees of freedom. They considered the most common 
!"#$%&'(')%(*
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approximation for a bacterium being propelled by a bundle of flagella, which is represented by a 
sphere being pushed at a point p on its surface. This paper examines the dynamics of the body of 
the bacteria in a two dimensional plane, focusing on the rotation of the cell body caused by the 
tangential component of the flagellum’s force along with the magnetic torque. In fact, 
considering a flagellum with a non-integer number of turns, which is essential to model the 
helical motion of the bacteria [97], the force ! acting on the cell body will be given by: 
! =     !!" !"# !" !! + !"# !" !! + !!!! (2.2) 
where ! is the angular frequency of the flagellum relative to the cell body, and !!" and !! are the 
tangential and longitudinal force. The tangential force !!" (see Figure 2.2 for the reference system) 
will induce a torque on the cell body given by: 
 !!" =     ! ⋅ !!" (2.3) 
where ! is the radius of the bacteria’s body. Considering a low Reynolds number regime where 
the hydrodynamic force is approximated as a pseudo-steady stokes drag, !!" and !! are given by: 
!!" =      !!"6!"# (2.4) 
!! =      !!6!"# (2.5) 
where η is the dynamic viscosity of the medium (for the purpose of this paper, we consider  the 
viscosity of water to be 1.002 Pas). 
Due to !!" and !!, the bacteria’s swimming path will follow a helical motion with a pitch angle !! given by: 
!"# !! =     !!"!!  (2.6) 
eqs 4 and 5 into eq. 3, the torque !!" on the bacteria’s body caused by the force !!" can be 
written as:  
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!!" =     6!"!!!!!"# !!  (2.7) 
The second torque that the bacterium’s body is subjected to is the  torque caused by the externally 
applied magnetic field, which is given by !! =     !×! = ! ⋅ ! ⋅ !"# !  (2.8) 
Where ! is the magnetic moment of a bacterium, ! is the external field and ! is the angle 
between them. This torque is generally considered negligible once the bacteria are aligned with 
the external field due to the small angle !. In fact, it is clear that this torque can be ignored at low 
field levels due to its insignificance compared to the hydrodynamic torque caused by the 
tangential force !!". However, at very high field levels, the magnetic torque increases to the same 
magnitude, if not greater, than the hydrodynamic torque. 
 
Figure 2.2. Reference system for the simplified model describing the dynamics of a magnetotactic bacteria. The 
magnetic torque results from the angle between the magnetosomes chain and the external field while the 
hydrodynamic torque is produced by the movement of the flagella on the cell body. The cell body is represented by a 
sphere. 
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2.2.5 Motion study 
The torque !!" caused by the flagella rotation can be estimated by measuring the pitch angle !! 
and the migration velocity !! at a zero gauss magnetic field, which balances the magnetic torque. 
Two pairs of orthogonal magnetic coils powered with opposite current provided the zero gauss 
magnetic field. Mean value for the MTB radius, as well as the magnetosomes dimensions were 
obtained from electronic microscopy. The pitch angle and the migration velocity were estimated 
for different magnetic field values ranging from 1 Gauss to 600 Gauss. 
2.3 Results and discussion 
2.3.1 Motion 
Magnetic field values above 200 Gauss cause observable changes to the motion of MC-1 under 
optical microscopy. As depicted in Figure 2.3, the application of a high magnetic field causes a 
decrease in the speed of MC-1 and an increase of the pitch angle of the spiral that describes the 
trajectory of the bacterium. This change is likely to be caused as a consequence of the magnetic 
torque being applied to the motion of the bacterium. In order to compare the magnetic torque to 
the hydrodynamic torque, we measured the longitudinal !!" and the tangential speed !! in the 
absence of a magnetic field and calculated the hydrodynamic torque using Equation 2.7. At a 
magnetic field of zero, as depicted in Figure 2.4, the MC-1 bacteria swim in circles confirming the 
negligible effect of the action of the magnetosome chain since non-magnetic bacteria have 
tendency of swimming in circles near boundaries [98, 99]. We established an approximate value 
of 1 ⋅ !!!"! ⋅! for the hydrodynamic torque. At geomagnetic field values, the magnetic torque 
is approximated by 1 ⋅ !!!"! ⋅!, which, in terms of magnitude, is 100 times smaller than the 
hydrodynamic torque. However, at 600 Gauss, the magnetic torque increases to 1 ⋅ !!!"! ⋅!, 
which is higher than the hydrodynamic torque. 
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Figure 2.3. Representation of MC-1 in a 15 Gauss and 600 Gauss magnetic field. When subjected to a strong 
magnetic field, the angle of pitch of the helical motion increases causing the longitudinal speed of the bacteria to 
decrease. It was possible to record the helical motion of MTB by increasing the shutter speed of the Sony camera 
used to transfer video recordings to a computer. 
 
The !! speed of MC-1 is always negatively affected by a high magnetic field, which suggests that 
the magnetic torque always adds to the hydrodynamic torque thus increasing the pitch angle of 
the helical motion. In order for this to happen, the orientation of the magnetosome chain within 
the bacteria must be coherent with the bacterial population, otherwise the pitch angle will 
decrease. Figure 2.5 shows three possible orientations of the bacteria’s internal magnetosome chain 
for a fixed hydrodynamic torque direction. In cases a and b, we can expect a decrease in the pitch 
angle which causes an increase in the !! speed, while configuration c will be the only one to 
cause an increase in the pitch angle and a decrease in bacterial speed. This simplified model does 
not account for the precession of the bacterial body nor for the difference in frequency between 
the rotation of the flagella and the cell body, it only suggests a relationship between the 
orientation of the magnetosome chain and the flagella axis. 
!"
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Figure 2.4. In the absence of a magnetic field, MC-1 travels in a circular motion that is characteristic of non-
magnetic bacteria swimming near boundaries. The zero magnetic fields were obtained by activating two pairs of 
magnetic coils with opposing current. In such a context, since the magnetic torque caused by the interaction of the 
magnetosomes chain with the external field is null, the hydrodynamic torque can be estimated with more accuracy. 
2.3.2 Magnetization reversal 
MC-1 change polarity when submitted to a high magnetic field. The change of polarity occurs 
only when the bacteria come in contact with a physical obstacle, such as the edge of the droplet. 
The polarity reversal is permanent. MC-1 sample normally contains 90% north seeking and 10% 
south seeking bacteria. After being submitted to a 600 Gauss field, 50% of the bacteria in that 
same sample become North seeking and the other half south seeking.   
This phenomenon can be explained using the model of the chain of spheres that describes the 
mechanism by which aligned spherical magnetic particles reverse polarity when the external field 
is reversed. The model was first introduced by Jacobs and Bean [95], in which they show that 
less energy is required for the spheres to reverse following a fanning mechanism than a coherent 
one. Jacobs and Bean, approximated the coercive force of a chain of 10 single domain 
nanoparticles reversing polarity following a fanning mechanism to a value of 2270Oe. The 
presence of imperfections in a chain of spheres causes the coercive force to decrease. This may 
explains why the change of polarity for MTB does not occur at the same magnetic field for all the 
bacteria in the sample. 
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Figure 2.5. Representation of three different configurations for the orientation of the magnetosomes chain influenced 
by an external field.  A and B are the only possible configurations where the magnetic torque adds to the 
hydrodynamic torque. 
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Figure 2.6. Artistic view of polarity reversal once a bacterium hits the edge of a droplet.  Because of the constant 
movement of the flagella when the edge is reached, the magnetosomes chain can be orientated in the opposite 
direction to the magnetic field. Single domain spheres assembled in a chain change polarity when submitted to an 
opposing magnetic field stronger than its coercive field. 
 
Figure 2.6 shows what we think happens to the bacteria prior to reversing direction as we apply a 
high magnetic field. First, the bacteria line up with the magnetic field and swim toward the edge 
of the droplet with a high pitch angle helical motion resulting from the high magnetic field. When 
the bacteria are near the edge of the droplet, the hydrodynamic interaction with the boundaries 
causes the bacteria to trace out round trajectories. Figure 2.7 shows a picture of MTB motion near 
the edge of the droplet for a magnetic field of 10 Gauss. The motion of the MTB is not aligned 
with the magnetic field anymore and a bacterium can swim for a short time against the magnetic 
field. For a very brief moment, the magnetosome chain will be subjected to an opposing strong 
magnetic field that will reverse the magnetosome chain polarity placing the flagella on the 
reverse side of the starting direction. Bacteria containing less or non-uniform magnetosomes will 
!"#"
!"$"
#" $"
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be more susceptible to the reversal of polarity than bacteria with a greater number of uniform 
magnetosomes. 
 
Figure 2.7. Magnetotactic bacteria swim by means of flagella. Helical motion is a consequence of the non-integer 
number of turns of the flagella spire. MTB follow the magnetic field direction as in (a), however, near boundaries 
and obstacles, their motion forms an angle with the magnetic field. 
 
 
The polarity reversal can be used to homogenize a bacterial sample so that it only contains either 
a north seeking or a south seeking population. In order to do so, four strong permanent magnets 
are positioned to face each other (North or South) in pairs in an orthogonal pattern. Figure 2.8 
illustrates how each population conducts itself in the sample. South-seeking bacteria will tend to 
gravitate toward and remain in the center while North-seeking ones will be attracted to the edge 
of the setup then reverse direction due to the polarity reversal caused by the high magnetic field 
at the magnet’s surface and finally settle in a neutral midpoint where force fields are neutralized. 
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Figure 2.8. Polarity selection magnetic setup. A sample containing both north-seeking and south-seeking bacteria 
will be transformed into a homogenous sample containing only one population using this magnetic setup. The setup 
is guided by four permanent magnets arranged so that two positive magnets face each other and two negative 
magnets also face each other North-seeking bacteria will be directed to the center and will stay there. South-seeking 
bacteria will be directed to the edge of the setup and reverse direction due to the high magnetic field near the magnet 
surface, and will head to the center where the field is null. Since polarity reversal is permanent, only one population 
will remain. 
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CHAPTER 3 A Magnetic Guidance System for Magnetotactic Bacteria 
Targeting Tumours 
 
3.1 Introduction 
A novel drug delivery technique using MC-1 Magnetotactic bacteria (MTB) is considered in this 
paper. MTB align and swim along the direction of an external applied field using flagella and an 
induced magnetic torque on a chain of nanoparticles called magnetosomes embedded in each 
bacterium [82, 100]. MTB possess all the needed components for effective targeting in the human 
vasculature, such as a flagellum, an internal magnetic sensor, an appropriate size and enough 
thrust [46]. The magnetosomes chain embedded in the cell makes the bacteria very sensitive even 
to weak magnetic fields. Besides the intrinsic characteristics of MTB, many gains can be 
achieved by using these microorganisms in drug targeting applications. First, MTB can help to 
uniformly distribute a drug into the tumour because of their active motility. Second, they could 
enhance embolization procedure since they don’t require blood flow in order to move in the 
vasculature and can reach cancerous cells even in the absence of flow. Third, the bacteria can be 
easily functionalized through antibody bond, or by the use of cell penetrating peptide (CPP) to 
name just a few methods. 
Close-loop control of MTB in targeting applications requires a tracking system, an external 
magnetic guidance system, and a control algorithm that adjust the direction of the magnetic fields 
according to the actual and the desired position. Since the Fe3O4 magnetic nanoparticles 
embedded in each bacterium are similar to the nanoparticles used as MRI contrast agents, 
tracking and in vivo imaging of MTB is possible using a clinical Magnetic Resonance Imaging 
(MRI) system [101]. Furthermore, the MRI also offers an environment for the real-time 
integration of the different modules required for the targeting procedure. A demonstration of the 
real-time navigation of ferromagnetic microdevices in the vascular system of a living animal was 
presented in [59, 61-63]. The same architecture could be used for MTB navigation, using an 
external magnetic field instead of the MRI internal gradient fields. In fact, the high static 
magnetic fields of 1.5 Tesla or higher inside the MRI bore prevent the navigation of MTB and 
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constraint their motion to the direction of the main field.  
Many options are available for MTB navigation; however, a special care is to be made in order to 
build a system compatible with the MRI machine since the magnetic guidance system will be 
placed as close as possible to the MRI bore. A sliding table will connect the interior of the MRI 
with the magnetic guidance system as in XMR-suite where a sliding table connects together the 
MRI scanner with an X-ray system [102]. We opted for magnetic coils instead of permanent 
magnets in order to minimize interference with the MRI machine since the magnetic coils can be 
turned off during the imaging phase, which is not possible with permanent magnet. 
3.2 Method 
3.2.1 Magnetotactic bacteria characteristics 
MC-1 magnetotactic bacteria are used in this experiment. MC-1 MTB are characterized by a high 
swimming speed (we recorded a peak speed of 300µm⋅s-1 in our laboratory), spherical shape and 
a typical size of 2µm of diameter. There is approximately 12 to 15 nanoparticles per cell having 
an approximate size of 70nm. The samples used for the experiments contain pre-selected bacteria. 
The pre-selection step aims to split the north seeking from the south seeking population and to 
select the most active ones. This is done by applying a homogenous magnetic field on the entire 
sample in the z-direction. The north seeking and south seeking bacteria go to the top and the 
bottom of a container respectively. We invert then the magnetic field and took a sample at a few 
centimeters from the top in order to get the fastest ones. The amount of bacteria was quantified 
using a Zeiss Imager.Z1 microscope. For this first characterization experiments, the bacteria was 
kept in their growth medium.  
3.2.2 Magnetotactic bacteria motion 
MTB moves due to their flagellar motion with the constant speed υ0. The direction of motion is 
dictated by the external applied magnetic field H as well as the rotational Brownian motion that 
tend to deviate the MTB from the field direction. The velocity υ0 can be divided into two 
components with respect to H as stated in [103]. Assume an angle of ϕ between the motion 
direction of the bacteria and the applied field H, the velocity component parallel and 
perpendicular to H are given by 
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 (3.1) 
 (3.2) 
The nanoparticles inside the cell however are arranged in chain in order to maximize the 
magnetic moment m of the bacteria. The angle ϕ will depend on the ratio between the magnetic 
energy and the thermal energy such as its time averaged expression will equals a Langevin 
function as described in [104] and given by 
 (3.3) 
where K is the Boltzmann constant and T the temperature, µ0 is the permeability of free space, 
and B the magnetic field density. 
Thus, the bacterial orientation with the magnetic field lines will be affected by the value of H as 
well as the temperature of the medium. The earth magnetic field of 0.5 Gauss exerts enough force 
on the magnetosomes chain to allow the overall motion of MTB to be in the direction of this 
field. However, at this field strength, the direction of MTB is greatly influenced by chemotaxis 
and aerotaxis. Considering a magnetic moment m of 10-16(A.m2) at room temperature (297.15K), 
the magnetic energy is 1.15 times the thermal energy when subjected to the earth's field. The 
magnetic energy becomes more important at higher field and we can expect that the bacterial 
direction will be specified by the magnetic field lines value greater than 4 Gauss, where the 
energy ratio is approximately 10. 
3.2.3 MTB guidance 
Different magnetic navigation methods can be used for MTB guidance. The simplest method 
consists on a three orthogonal Helmholtz pairs generating a homogenous magnetic field in 3D 
space. By powering the coils accordingly any field direction can be generated. While this method 
could be effective, it is evident that obstacles such that found in the anarchic arteriocapillar 
networks found in tumours are a limiting factor.  
0 cosHυ υ ϕ= ⋅
0 sinυ υ ϕ⊥ = ⋅
0cos , where 
mBL B H
KT
ϕ µ⎛ ⎞= =⎜ ⎟
⎝ ⎠
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Another method using 3-axis Maxwell coils that is better suitable for tortuous paths could be 
used instead. The Maxwell configuration causes the MTB that follows the magnetic field lines to 
be trapped in the center of the coils. Controlling the motion of the bacteria is done by changing 
the current ratio between coils of the same pair. Since the current flowing in each coil of a 
Maxwell pair should be the same in order to have a linear gradient, having different current in 
each coil of the same pair will lead to a non-linear gradient. The relationship between the ratio of 
I1 and I2 (current in each coil of a Maxwell pair) and the position of the zero magnetic fields is 
plotted in Figure 3.1. We choose to change only one current value at a time. Therefore, depending 
on the displacement side, one current value is set to the maximum while the other is changed 
according to the desired position. The mathematical relationship between the zero field position 
and the current ratio is given by 
 (3.4) 
where I1(A) and I2(A) are current in each coil of the Maxwell pair, r(m) is the radius of the coil, 
d(m) is the distance between the coils and z(m) is the required position. 
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Figure 3.1. Changing the current value for one coil of a Maxwell pair causes the position of the zero fields to move 
from the center. However, the gradient linearity is no longer preserved. 
 
3.2.4 Magnetic guidance system 
A novel magnetic field strategy for efficient navigation of MTB is proposed. This method uses a 
combination of Helmholtz and Maxwell coils. It consists on 3-axis Helmholtz coils controlling 
the position of the magnetic field convergence point generated by a set of Maxwell coils. In fact, 
as depicted in Figure 3.2, a linear relationship stands between the current flowing in the Helmholtz 
coils and the position of the zero fields generated from the Maxwell pairs. 
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Figure 3.2. The relationship between the current IH flowing in a Helmholtz pair and the displacement value of the 
Maxwell magnetic fields. 
 
3.2.4.1 Helmholtz pairs 
In this experiment we used 3-axis square Helmholtz coils having dimensions of 20×20×20cm. 
The coils have been spaced by 0.5445×L, where L is the length of one side. The maximum 
magnetic field that could be applied in continuous was 15 Gauss obtained with a current of 2A. 
We decided to use a cube frame for the Helmholtz coils in order to gain space since another set of 
coils is to be inserted inside. We achieve excellent homogeneity (field discrepancies < 2%) in 
approximately 10×10×10cm around the center. Furthermore, the cube frame allows the three coil 
pairs to be approximately the same size.  
It is possible to develop an explicit form for the total magnetic field produced by a pair of square 
Helmholtz coils. For that, each side of the coil could be considered separately as a current 
carrying wire. Superposition of the contribution of each segment forming the pair of the square 
coils with appropriate rotation gives the final equation. 
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3.2.4.2 Maxwell pairs 
A smaller 2-axis circular Maxwell coil set was used to generate a linear gradient. The first pair 
has a radius (r) of 6cm while the second was 8cm. The coils were spaced according to the optimal 
Maxwell relationship which is r×sqrt(3) and supplied with equal but opposed currents. The 
maximum gradient that we could continuously apply was 0.5 Gauss/mm. The Maxwell coils were 
connected in parallel and powered by one power supply while each Helmholtz coil was 
connected separately to a power supply. A software running on a computer allows to manipulate 
in real-time the current value of the power supplies using a GPIB controller (model) as depicted 
in Figure 3.3. 
 
Figure 3.3. Automatic navigation of MTB is done using a computer controlling the power supplies through a GPIB 
interface. 
The longitudinal component of the magnetic field and the magnetic field gradient produced by 
two electrical current loops are given by, 
 
(3.5) 
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where, N  is the number of loops in the coil, a is the radius of the loop, µ0 is the vacuum 
permeability, i is the electrical current, d is the distance between the coils, and z is the position 
along the longitudinal axis of the loops. 
3.3 Results 
3.3.1 Magnetic field simulation 
The resulting magnetic field from the Maxwell pairs is as depicted by Figure 3.4 a and b for two 
orthogonal pairs. Whatever the location of the bacteria before applying the magnetic field, they 
will all be directed to the center after the magnetic field is applied. This simulation is done for the 
2D case; in order to apply the Maxwell magnetic field in 3D space a temporal multiplexing is 
required. In fact, each coil will have a longitudinal component of the magnetic field, the one 
required for MTB trapping, and a transversal magnetic field. The transversal field from one coil 
is opposite to the longitudinal component of the transversal coils. Since the longitudinal 
component has higher amplitude than the transversal one, the resulting magnetic field will be 
enough high for bacterial trapping. However, If three pairs are powered at the same moment, 
each direction will have a longitudinal component added to four transversal components, which 
will cause an almost cancellation of the longitudinal field. In order to apply a Maxwell field in 
3D, the coils have to be powered by group of two pairs. Since there is 3 different combinations, 
each group of coils has to be powered 1/3 of the time period. 
3.3.2 Magnetic field MTB sensitivity 
The bacteria will be trapped between the Maxwell coils as depicted in Figure 3.5; the region extent 
where they accumulate depends on the gradient intensity as well as on their sensitivity to the 
magnetic fields. The MTB sensitivity to the magnetic field depends on their magnetic moment 
that depends on the number of magnetosomes in the cell. It is believed that mature cell contains 
twice as much magnetosome as a younger one. For that reason, when studied under microscope a 
different response and sensitivity to the magnetic field is observed. When submitted to a 
magnetic gradient of 0.5 Gauss/mm and observed at a macroscopic scale, the bacteria form a 
visible circle of 3.5 mm of diameter. Thus, we can conclude that most of the MC-1 MTB that we 
use are sensitive to a field as weak as 0.8 Gauss. As shown by the contour plot, the magnetic field 
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at the centre is null. When reaching this region of zero field, the MTB are free to move in every 
directions until it reach a magnetic field that will bring them to the zero field region again. 
 
 
Figure 3.4. a) On the plane magnetic field velocity vector generated from 2D Maxwell pairs. b) Magnetic field 
absolute value as generated by a two Maxwell coil pairs in the x and y-axis. The magnetic field lines are directed 
toward the center where the field intensity is zero. 
 
 
 
Figure 3.5. This figure shows an MTB sample under the influence of the Maxwell magnetic field. The bacteria from 
the entire sample are directed to the center of the container. The magnetic field gradient was 0.5Gauss/mm. 
 
  42 
 
 
3.3.3 MTB guidance 
The Helmholtz coils are able to offset the Maxwell magnetic field linearly in all directions of 
space. A demonstration for the guidance of MTB is shown in Figure 3.6. Two minutes after the 
Maxwell coils were powered, a bacterial accumulation becomes visible in the zero magnetic field 
regions as depicted by Figure 3.6 (a, b). The MTB continued to accumulate for three more minutes 
after which the set point was changed. The controller computed then the current to be applied to 
the Helmholtz coils and sent these values over a GPIB card to the power supplies. The MTB 
follow the new target, barring those stacked on the beaker surface as shown in Figure 3.6 (c, d, e, 
f). 
3.4 Discussion 
Trapping MTB by a gradient magnetic field in the target site may show many advantages over 
traditional MTB guidance. In fact, this method has the advantage to more likely uniformly 
distribute the drugs inside target region. In addition, the low magnetic field applied in the target 
region, which can be a tumoural lesion, gives freedom to the bacteria helping them to avoid 
obstacles that can encounter on their ways. In fact, a tumour forms a lot of capillaries through 
angiogenesis that have the characteristic to be leaky, irregular and misformed, with non-uniform 
blood flow preventing many drugs to attain the entire cancerous cells.  
Gradient magnetic fields are also used to trap micro and nanomagnetic particles in a targeted 
region of the human body, which is commonly dubbed Magnetic Drug Targeting (MDT) [51, 52, 
105, 106]. Because the magnetic force acting on the magnetic particles is proportional to the 
gradient fields as given by 
  43 
 
 
Figure 3.6. MTB guidance demonstration. In (a) and (b) a gradient was applied using the Maxwell coils. From c to f, 
the target location was changed which imply the activation of the Helmholtz coils. 
 
 (3.7) 
high values are required for efficient trapping. In Equation 3.7, m (A.m2) is the magnetic 
moment, µ0 (N.A-2) is the permeability of vacuum, H (A·m-1) is the magnetic field, and Fmag (N) 
is magnetic force. Table 3.1 summarizes the gradient field used in typical trapping applications 
involving MDT. For purpose of comparison the magnetic field gradient required to trap MC-1 
MTB in a 1 mm diameter sphere area is also given. We notice that the gradient required to trap 
MTB is much less than that required for micro and nano magnetic particles trapping. 
 
 
 
 
 
HmFmag
 )..(0 ∇= µ
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Table 3.1. Summary of some examples of the magnetic particles and the gradient required for their trapping 
 
 
3.5 Conclusion 
Bacterial tumour targeting has gained renewed interest these last years because of the ability of 
some bacteria to reach deep tumour region and induce a therapeutic effect [68, 70, 107]. 
However, we propose a new mechanism of drug delivery using magnetically controllable 
bacteria. We show the magnetic control of MTB using a novel magnetic navigation strategy 
adapted to operate close to an MRI system.  Future works will be directed toward closing the 
loop of the magnetic control and MRI tracking in order to be able to navigate MTB through 
complex pathways and in vivo in real-time. 
 
 
  
  
MAGNETIC 
PARTICLES 
MEAN 
DIAMETER 
(µm) 
MAGNETIC 
GRADIENT 
(T·m-1) 
Reference 
Magnetite 0.0156 10-30 [12] 
Mn-Zn ferrite 2 26 [13] 
Maghemite 0.03 4.5-18.8 [14] 
Magnetite 0.25 5-70 [15] 
Magnetite 10.9 0.443 [5] 
MC-1 MTB 2 0.2* - 
*The gradient is calculated to trap the bacteria inside a spherical area having a 1mm 
diameter.  
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CHAPTER 4 MC-1 MAGNETOTACTIC BACTERIA NAVIGATION 
AND CONTROL WITHIN SMALL PHANTOM VESSELS: TOWARD 
BACTERIA TUMOUR TARGETING 
 
4.1 Introduction 
Anticancer therapy effectiveness depends mainly on two parameters; first, the intrinsic efficacy 
of the anti cancerous agent used, second, the quantity by which the agent reach the tumour [108]. 
The intensive research on cancer therapy of the past 20 years have led to a good understanding of 
the tumour biology and have brought many effective anticancer drugs up to the market. However, 
due to many physiological barriers that blood-borne agents encounter, the amount that reaches 
the tumour is often negligible compared to what was injected in the blood network [109-112].  
The most common set of parameters affecting the delivery of blood-borne anticancer drugs to 
tumours are:  The miss-formed angiogenesis capillaries supplying tumours, the high interstitial 
pressure inside solid tumours as well as the blood flow heterogeneity of vessels supplying the 
tumour. These parameters have as consequences the diminution of therapeutic reaching the 
target, the non-uniform distribution of drug inside the tumour and the increase of the time 
required for a drug or molecule to be in direct contact with the cancerous cells. 
In order to overcome some of the limitations that have been just addressed, we propose to use 
living flagellated bacteria to target tumours. Magnetotactic bacteria (MTB) [46, 82, 83] have 
been chosen due to their ability to orient with an applied magnetic field and to swim persistently 
in that direction. MTB synthesize intracellular Fe3O4 nanoparticles, called magnetosomes, 
assembled in a chain acting as a compass to influence through magnetotaxis the swimming 
direction of the bacteria. Computer control of the motion direction of these microorganisms is 
then possible using a set of magnetic coils or permanent magnet. The MTB cell size ranging from 
1 to 3µm in diameter gives them the ability to navigate in the smallest capillaries network, 
especially the malformed ones of a tumour. There are many MTB strains available in nature, but 
because of their high swimming speed, reaching 200 to 300µm, the MC-1 MTB was chosen as a 
potential candidate for this application.  
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Bacteria are believed to have a great potential in targeting the hypoxic zone of tumours, that other 
therapy fail to treat. According to [113] a set of criteria have been defined for a successful 
bacterial cancer therapy. MTB fulfill much of these requirements in order to be an efficient 
bacterial tumour targeting system. In fact, MTB do not have any known toxicity or related 
infection. Furthermore, they can selectively target tumours by direct navigation using controlled 
magnetic fields. Their active motility and high speed should help to uniformly invade the tumour 
and to access the quiescent and hypoxic region of it. However, unlike standard bacterial therapy 
approach, neither survival nor growth at the body temperature is expected from MTB. The 
overall MTB targeting procedure is limited to the time the bacteria remain active and alive at the 
body temperature, which is estimated to be between 30 to 45 minutes, unless a local temporal 
temperature decrease is apprehended.  
Due to the little time frame available for MTB delivery to targets, efficient magnetic control is 
required. However, the major problem consists on the lack of knowledge on the internal tumour 
blood vessels architecture. Taking into account the bacteria speed, their magnetic sensitivity as 
well as their behavior at different field strength, the direction and intensity of the magnetic fields 
applied for guidance can be optimized. 
4.2 Method 
4.2.1 Magnetotactic bacteria characterization 
We characterized the swimming of MTB in vitro by mimicking different situations that they 
could encounter in an in vivo environment. The characterization goal was to be able to predict the 
MTB behavior in a complex microvasculature network and to choose the correct magnetic field 
algorithm that has to be applied to obtain optimum targeting. In fact, as the MTB follow the 
magnetic field, they could be stuck easily into obstacles especially in a very complex capillary 
networks such as the tumour angiogenesis. As a consequence, changing the direction of the field 
is necessary to guide the bacteria. The problem is that there is no visual information on the route 
and obstacles that the bacteria are facing. 
The bacteria motion speed and magnetic sensitivity are the two main factors that mostly affect the 
targeting procedure. These two factors however, do not follow exact science rules; they could 
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change from one sample to another as a consequence of changes in the growth or experimental 
conditions. 
4.2.1.1 Growth condition 
Magnetococcus sp. (MC-1) was grown in chemoheterolithotrophic liquid medium under 
microaerobic conditions. Iron-enrichment of the medium was done using 50µM of ferrous sulfate 
heptahydrate FeSO4⋅7H2O (F8048, Sigma-Aldrich). 
4.2.1.2 Speed measurement 
A sample containing MTB were deposited on a microscope slide, a cover slip placed over the 
drop using 450µm separators to form a pool in the center. The slide was then placed on a 
microscope stage (AxioImager Z1, Carl Zeiss Imaging solutions) under dark-field illumination. 
Image acquisition was made by AxioCamMr (Zeiss) using a 20× LD Ediplan lens magnifier. The 
exposure time was set to 200ms allowing the visualization of the trail left by bacterial motion. All 
measurements were made using the AxioVision v.4.6.0 software. 
4.2.1.3 Magnetic field sensitivity 
MTB population distribution under various magnetic field values generated using an orthogonal 
pair of magnetic coils was determined after image analysis.  Magnetic sensitivity is estimated by 
counting the number of bacteria inside a given equipotential magnetic field. ImageJ v 1.42q 
software was used to count bacterial cell distribution. 
4.2.2 Magnetotactic bacteria guidance 
The experimental setup, for the in vitro MTB guidance, is composed of three parts. The first part 
is an optical system consisting on a Zeiss microscope (Stemi SV 11) with a Sony camera (DCR 
HC1000) connected to a computer through a firewire link. The second part is a tridimensional 
magnetic coils system (Resonance Research, Inc. Billerica, Massachusetts) powered by GPIB 
computer controlled power sources (Sorenson XG 1700, AMETEK Programmable Power, Inc. − 
San Diego, CA). The last part consists on a microfluidic channels where the bacteria are 
navigated and targeted. 
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4.2.2.1 Magnetic control system 
Two pairs of the tridimensional magnetic control system served for navigation, while the third 
pair insured the magnetic field is less than 0.5 Gauss along the orthogonal direction. The 
reference system is as given by Figure 4.1. The coils, along the x and z directions, were powered 
with opposed current as in a Maxwell configuration as illustrated in Figure 4.1 (a). Changing the 
current ratio between coils of the same pair changes the zero field position along that axis. Since 
MC-1 MTB are unipolar and follow the magnetic field direction, they will be trapped in this zero 
field region. Automatic control of the position of the bacteria is granted through repositioning the 
zero field position. The mathematical relationship between the target position along one axis, and 
the current ratio is given by 
!1!2 = !! + ! + !! !!! + ! − !! !!  (4.1) 
where !1 (A) and !2 (A) are current in each coil of a pair, ! (m) is the radius of the coil, ! (m) is 
the distance between the coils and ! (m) is the target position. 
  49 
 
 
Figure 4.1. Magnetic field generated by two pairs of orthogonal magnetic coils, powered by opposite current as 
shown in (a). The in-plane magnetic field is shown in (b), while the magnetic field in the orthogonal direction is 
shown in (c). The magnetic field direction in (a) converges to the center of the coils, causing the bacteria to 
aggregate in this point. In the orthogonal direction, however, the magnetic fields direction diverges. 
4.2.2.2 Micro-channels network 
A design consisting on a multiple U-channels shape as depicted in Figure 4.2 was used for 
targeting experiment under microscope. The shape of the channels does not represent patterns 
that can be found in the microvasculature of a tumour, however, it does offer a pattern that can be 
reproduced precisely with computer simulation tools. The microchannel have a diameter of 
100µm. 
!"#$%&!"#$'&
!"#$(&
!"#$)&
*&
+&,&
*&
+&
)&-./00&
*&
,&
)&-./00&
1& 2&
.&
!'&
!%&
!(&
!)&
  50 
 
 
Figure 4.2. Microfluidic channel used for in vitro bacteria targeting. The channel have a diameter of 100µm. There is 
two entry points to the channel as well as two exits (not shown in the picture). The channel was filled with PBS 
(Phosphate Saline Buffer), prior to the deposition of the bacteria in the insertion points. The bacteria are inserted 
without any pressure to ensure that the ones reaching the target are under the action of the magnetic field. 
4.2.2.3 Magnetic Field and bacteria targeting simulation 
Equation 4.1 was numerically solved, for the two pair of coils, using MATLAB (The 
MathWorks, Natick, MA) and integrated in a computer program that generates a text file 
containing current to apply on each coils to create a given sequence of magnetic fields. The 
microchannels were simulated using a 2D matrix having zeros in the interior of the channels and 
ones otherwise. We used a simple model for a particle following the magnetic field to simulate a 
bacterium. When a simulated bacterium hits a wall, it follows the direction of the magnetic field 
that is orthogonal to that obstacle. Simulation served mainly as a visual aid and as illustrations 
purpose, however, the behaviour of bacteria is much more complex than our model especially 
when they hit obstacles. 
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Figure 4.3. MTB distribution in a gradient magnetic field. The MTB lie inside the 0.3 Gauss magnetic equipotential 
circle, with more than half of them inside the 0.1 Gauss equipotential.   
4.3 Results 
4.3.1 Magnetotatic bacteria characterization 
Figure 4.3 shows the MTB’s distribution in a spatially varying magnetic field. The bacteria 
distribution map, thus obtained, can help to define the sensitivity range and the strength of the 
magnetic fields to be applied for navigation. The number of bacteria per equipotential is plotted 
in Figure 4.3. The MTB gather inside the 0.3 Gauss magnetic equipotential circle, with 
approximately 68% inside the 0.1 Gauss equipotential. The bacteria are in continual random 
motion in this zone since the magnetic field is very weak. The magnetic torque that is responsible 
for aligning the bacteria with the magnetic field is given by 
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 !! =     !×! = ! ⋅ ! ⋅ !"# !  (4.2) 
where ! is the magnetic moment of a bacterium, ! is the external field and ! is the angle 
between them. As soon as a bacterium reaches a certain field that causes the bacteria to realign 
with the magnetic field, it is sent back to the center of the magnetic fields. The magnetic moment ! of a bacterium is given by the properties of its magnesomes chain, and more specifically, the 
number of nanoparticles and their size. According to these results, the 0.3 Gauss equipotential 
was chosen as boundaries limit for specifying the target region during the navigation experiment 
tests. 
4.3.2 Magnetic Bacteria navigation in microfluidic channel 
The bacteria are deposited on the insertion tank without applying pressure to insure that the 
bacteria do not attain the target under the action of flow. Furthermore, the shape of the 
microchannels is enough complex to make sure the bacteria do not reach the target following a 
random motion. These two facts were experimentally validated before conducting magnetic 
navigation experiments. 
When the target location is set to the first U-shape channel the bacteria were able to reach the 
target, as depicted in Figure 4.4.  In Figure 4.4 (a), we show the magnetic field applied as well as the 
target location. The circle denotes the magnetic field region where the field has an intensity of 0.3 
Gauss. In Figure 4.4 (b) we show the microscope image of the bacteria submitted to the field 
presented in Figure 4.2 (a). Simulation as well as experiments showed that it is possible for the 
bacteria to exit through the insertion tanks and accumulate in the target zone. However, when the 
target location requires traveling through the microchannels maze, as it is the case shown in Figure 
4.4 (c), no bacteria were able to reach the target. In fact the magnetic fields are orthogonal to the 
wall of the microchannels, and cause the bacteria to stick to the boundaries without being able to 
change direction. Furthermore, the intensity of the magnetic field is high far from the target and 
decrease to zero on the target spot. Since the swimming direction of MTB is given by a balance 
between the aligning magnetic energy (mB) and the thermal energy (KbT), far from the target the 
bacteria are enforced to follow the direction of the magnetic field, while near the target their 
direction is loosely related to it. Due to the dimensions of the channels and their 90 degrees 
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angle, the imposed magnetic field makes the bacteria stuck as if they hit a wall especially when 
they are far from the target, as depicted in Figure 4.4 (c). This magnetic control method does not 
cope with micro-channels having very complex pattern especially the tortuous micro-fluidic 
network used for this experiment. 
 
Figure 4.4. Targeting test in microfluidic channel. In (a) simulation of the magnetic field for a target location at the 
first U-shape occurrence in the channel. In (b) the corresponding MTB accumulation for the same magnetic field 
applied in a real channel with the same geometry. (c) When the converging field is set at another location, the 
bacteria are not able to bypass obstacle caused by the channel shape and to get to the target. 
4.3.3 Magnetic control considering the microchannels geometry 
Only when the applied magnetic field takes into account the phantom geometry that targeting 
becomes successful. In fact, Figure 4.5 shows what happen when the field translates around the 
target location instead of being static. The bacteria, in this case were able to go in the direction of 
the target without being stuck into obstacles. Figure 4.6 is a microscope image of the bacteria 
traveling the microchannels following the pattern shown in Figure 4.5. Magnetic field algorithm 
becomes very important in order to navigate accurately the bacteria, and can be generalized to 
complex geometries. Taking into account the geometry of the channels, the bacterial speeds and 
behavior for a given magnetic field, we can apply magnetic fields that optimize targeting. 
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Figure 4.5. MTB magnetic control taking into account the geometry of the micro-fluidic channels. 
 
 
Figure 4.6. Optical microscope images sequence showing the MC-1 MTB traveling in a microchannel following a 
given pattern. 
 
!"#" $"
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4.3.4 Magnetic control considering the microchannels geometry 
The goal of this control method is to prevent the bacteria from being stuck in the 
microvasculature, while, automatically assign a target zone in order to cope with the lack of a 
road map. As depicted in Figure 4.7, modifying the shape of the target zone has as a consequence 
to change the direction by which bacteria attain the target without deviating the ones that already 
reached it. This is achieved through unbalanced current intensity between the two pairs of the 
coils system. Another approach would be to target smaller zones inside the target area that would 
be offset regarding the center as shown in Figure 4.8. Multiplexing in time several of these control 
methods can increase the outcome of the targeting procedure. In fact, targeting becomes possible 
even in complex microfluidic channels even if it takes more time. The bacteria navigate towards 
the target area in the U-channel using a two-time control method. As a matter of fact, having 
some knowledge of the architecture of the channel may help efficiently choose the control 
algorithm to employ. Even in the case of the tumour, several characteristic patterns exist and 
discussed in the literature. 
 
Figure 4.7. Unblanced gradient from the two pairs of coils changes the shape of the target zone, delimited by the 0.3 
Gauss equipotential. Far from the target, the magnetic field specifying the direction of the MTB changes helping the 
bacteria to avoid obstacles. 
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Figure 4.8. By using higher gradient, smaller targets inside the main one, can be specified, causing the far field to 
change direction. This technique can helo the bacteria to avoid obstacles. 
4.4 Discussion and conclusion 
The navigation approach we adopted consists of focusing a magnetic on the target. This strategy 
allows us to designate the target without imposing a specific way for the bacteria to reach it. This 
is especially pertinent for applications where a road map is not available. Modulating the 
intensity and the direction of the magnetic field lines, while keeping them directed toward the 
target, may prove to be advantageous in an in vivo targeting context.  
The advantage of using bacteria to target tumours resides in their ability to target hypoxic zones 
that are characteristic of the center of solid tumours. Moreover, due to their active motility, 
bacteria can be an effective drug delivery agent by profiting from the leakages, reduced blood 
flow, and irregularities of the tumours vasculature. The commonly used bacteria belong to the 
Clostridia, Salmonella and Bifidobacterium strains. They can be genetically modified to express 
a certain gene that can have an antitumour effect or to suppress certain genes to strengthen the 
body’s tolerance to them. The therapeutic effect comes from the bacteria thriving from 
consuming necrotic cancerous tissue, or from products such as endotoxins that can be used for 
the destruction of tumours. Bacteria can also be used as delivery agents for anticancer drugs and 
as vectors for gene therapy. When the bacteria is administered in combination with 
chemotherapy, extensive hemorrhagic necrosis of the tumours results in significant and 
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prolonged antitumor effects, which is best known as combination bacteriolytic therapy 
(COBALT).  
Even though the preferential replication and accumulation of bacteria in tumours was proven, 
bacteria cancer therapy must face many challenges before it can become clinically effective. The 
first major limitation is the necessary high dose required to induce a significant therapeutic effect; 
this is often associated with severe toxicities. The inefficiency of bacteria to target small tumours, 
where a hypoxic zone has not yet been formed, constitutes the second major limitation. Also, 
combining bacterial therapy with other conventional methods, such as chemotherapy or 
radiotherapy, is mandatory in most cases for complete tumour consumption. Some of these 
limitations can be removed by using magnetotactic bacteria, the only living microorganisms to be 
proposed as a computer controllable drug delivery agent to solid tumours. 
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CHAPTER 5 A PLATFORM AND METHOD TO AGGREGATE AND 
CONTROL THE DISPLACEMENT OF MAGNETOTACTIC BACTERIA 
IN 3D VOLUME 
5.1 Introduction 
Magnetotactic bacteria (MTB) can be considered as self-propelled micro-bio-actuators or 
microcarriers in diverse applications where accurate computer directional control can be achieved 
by inducing a torque from a low intensity magnetic field. This torque acts on a chain of 
membrane-based nano-crystals known as magnetosomes, which operates like a magnetic nano-
compass or nano-steering system embedded in each bacterial cell.  MC-1 MTB also propel 
themselves with a flagella generating a thrust exceeding 4.0pN. Such features in this bacterial 
thus exhibit a highly advantageous mobility. This property, coupled with appropriately oriented 
computer-controlled magnetic fields of only a few Gausses, can be exploited for precise tasks on 
a nanometric scale. Notable examples to be cited are micromanipulation, microassembly and 
potentially, targeted drug delivery to tumoral sites in mice models, which has been demonstrated 
experimentally. In order to scale the force required to perform microassembly tasks, to propel 
future microrobots, or to increase the dose of therapeutic agents carried by the bacteria to a 
tumoral site, the ability of aggregating a required number of MTB within an adequate 3D volume 
and to move such aggregates in any desired directions becomes not only critical but essential. In 
this paper, a fundamental example of platforms referred to here as magnetotaxis systems is 
described. Such systems are based on a specific configuration of magnetic coils capable of 
producing a magnetic field environment to enable the formation of an aggregate within a given 
volume and to control its position in a 3D space using computer software.  
5.2 Motile bacteria as micro-actuators 
Over the last few years, motile bacteria have been considered as micro-actuators in engineered 
applications and systems to overcome the scaling limitation of previous methods of micro-
actuation, including but not limited to the integration of an embedded miniature source of power. 
Yet, it is currently impossible to implement motor technology at such a microscale in accordance 
to existing modern engineering techniques. Initial applications relied on a system analogous to 
rafting, where an array of motile bacteria were attached to a flat surface, their flagella oriented in 
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such a way to collectively generate a fluid motion in microfluidic channels [114, 115]. However, 
the motility of flagellated bacteria was later exploited to propel or transport miniature objects 
[116] or as integral components in engineered micro-systems such as in micro-rotary motors 
[117] without directional control. But it was soon recognized that directional control was pivotal 
to fully exploit the capability of the bacteria to perform accurate tasks such as transporting a 
miniature object along a pre-planned trajectory. Although motile bacteria can respond to a variety 
of stimuli such as chemical gradients (chemotaxis), light (phototaxis), or oxygen gradients 
(aerotaxis), to name but a few examples, these stimuli cannot always be accurately controlled in a 
given space and may result in inaccurate directional control, such as run-and-tumble motions in 
chemotaxis gradients. Hence, the choice of an inappropriate stimulus would not only result in 
more difficult directional control if feasible, but would also limit their usage for applications 
requiring precision such as in micro-assembly that relies not only on an instant bacterial reaction 
but also on a continuous and accurate response to the directional control stimulus. 
5.3 Bacterial transport application 
The first bacterial transport application under directional control was reported in [46] where a 
single magnetotactic bacterium (MTB) [82, 83] (overall diameter of the cell between 1-2µm) 
under magnetotaxis [118] directional control was used to push a micro-bead along a planned 
trajectory. Later, other experiments proved that several flagellated bacteria could be used to move 
a larger microstructure using phototaxis [119] or as demonstrated in following experiments, 
electro-kinetic directional control [120]. Unlike electro-kinetic control that act on the 
microstructure and not on the bacteria, both phototaxis and magnetotaxis directional control have 
the advantage of directly influencing the bacteria while preserving its independent movement 
upon the specific properties of the object transported. Furthermore, although phototaxis and 
magnetotaxis modes of control are likely to be much more scalable  ⎯ they can potentially 
operate on a larger working space due to the lower energy required for directional control, since 
no pulling force generated by an external source is involved ⎯ applications involving larger 
working volumes can be more easily supported. 
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5.4 The magnetotaxis advantage 
Nonetheless, magnetotaxis directional control can prove to be advantageous over phototaxis 
control in particular applications, including but not limited to the delivery of  therapeutic loads to 
targeted tumoral regions in the human body [44]. Indeed, not only could phototaxis control be 
limited by the effective depth of light penetration into the body, but also by not being able to 
allow the formation of an aggregate of bacteria within a tridimensional space. Such capability of 
aggregating the bacteria within a tridimensional volume could prove to be critical in enhancing 
targeted drug delivery through hard to access and unpredicteable microvasculature, while 
allowing the adjustment of therapeutic dosages by forming aggregates with a specific number of 
drug-loaded bacteria. The formation of such aggregates and its displacement control could also 
enlarge the range of applications in micromanipulation and microassembly tasks. Scaling the 
propelling force when attaching bacteria to a microscale object, such as a microstructure or a 
microrobot, is limited by geometrical features. For instance, the bacteria must be attached to the 
exposed surface and oriented in order to allow motion in the desired direction as it was the case 
in all previously mentioned examples.  However, more flexibility in scaling force can be 
achieved without attaching the bacteria to an object by using instead an aggregate possessing the 
required number of bacteria aligned according to magnetotaxis directional control. Their flagella 
can then be oriented in order to collectively generate a fluid motion that would exert a 
displacement force on the manipulated micro-object while retaining the possibility to dispatch the 
same aggregate in order to perform more complex microassembly tasks. This principle was 
validated experimentally in [121] where an aggregate of approximately 5000 MC-1 MTB was 
controlled to assemble micro-bricks as a miniature replica of an Egyptian Step pyramid in less 
than 15 minutes. The experimental data gathered showed that a larger aggregate could actually 
push a micro-object faster, suggesting that bacteria at a certain distance from the manipulated 
object could also have an effect on its displacement. Preliminary analyses suggest that this long-
range interaction between the bacteria and the micro-object happens through the surrounding 
fluid and could be related to the phenomenon of bioconvection. 
5.5 Aggregation platform  
In all cases, the workspace in which magnetotaxis control is exerted to force the MTB to 
aggregate and to move them in any directions must be within a proper magnetic environment 
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generated and controlled by what is referred to here as a magnetotaxis system or platform. For 
directional control of the MC-1 MTB for instance, such magnetotaxis platform generates a 
magnetic field to induce a directional torque on a chain of Fe3O4 magnetic nanoparticles known 
as magnetosomes that each MTB synthesizes during the growth phase. This magnetic torque 
aligns the bacteria along the direction of the external field while the bacterial flagella propel the 
cell forward. Although there can be variations in system’s implementations, the fundamental 
magnetotaxis platform described here relies on three orthogonal pairs of magnetic coils. Each coil 
is separately powered by a programmable power supply enabling us to generate either a 
homogenous or a gradient magnetic field. A gradient field is used to aggregate the MTB while a 
homogenous field controls the motion of the aggregate. 
5.5.1 Bacteria swarm formation 
The gradient field shown in Figure 5.1 (a) is generated by two pairs of identical magnetic coils 
powered with the same electrical current amplitude but flowing in opposite direction (Maxwell 
configuration). In this particular example, this magnetic field configuration causes the bacteria 
swimming over a substrate to be constrained in a region referred to here as the aggregation zone 
where the magnetic field lines converge towards a zero Gauss location as illustrated by the 
arrows length in Figure 5.1 (a). The periphery of the aggregation zone is not at zero Gauss but at 
the higher magnitude of magnetic field that is unable to induce a sufficient torque on the chain of 
magnetosomes of the MC-1 cells in this particular case for directional control purpose for 
unconstrained aggregation zone, i.e. without obstacle preventing the migration of the MTB. 
Indeed, when gathered in the aggregation zone as depicted by Figure 5.1 (b) the MTB follow a 
continuous free circular motion as shown on the figure. Hence, once aggregated, the motion of 
the MTB is restrained inside the aggregation zone delimitated by a boundary where the magnetic 
field is less than a threshold that results in magnetotaxis directional control to be no more 
effective. Experiments estimate this threshold to be 0.3 Gauss for the MC-1 MTB with 
approximately 50% of the bacteria in the sample being inside the magnetic field equipotential of 
0.1 Gauss.  
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Figure 5.1. Magnetic gradient field used for MTB aggregation and swarm formation. Once the bacteria enter the area 
where the magnetic field is less than 0.3 Gauss, they begin to move in circle.  
 
5.5.2 Bacteria swarm directional control 
The size of the aggregate can be controlled by the magnitude of the gradient magnetic field where 
increasing the magnitude of the electrical current flowing in each coil result in a denser and 
smaller diameter aggregate. Changing the current ratio between the coils of the same pair shifts 
the aggregation zone position along the axis joining both coils. Therefore, moving the aggregate 
of MTB from one location to another can be done by repositioning the aggregation zone. The 
mathematical relationship between the target position along one axis, and the current ratio 
powering two coils of the same pair is given by 
!1!2 = !! + ! + !! !!! + ! − !! !!  (5.1) 
where I1 and I2 are the currents powering each coil, r (m) is the radius of the coils, z (m) is the 
position of the aggregation zone and d (m) is the distance separating the coils. 
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A simple method to move an aggregate of MC-1 MTB is presented in Figure 5.2 where the 
aggregate’s initial position (represented by a circle in the center of the field) and the final position 
(represented by a dotted circle) are depicted. In order to form the initial aggregate in the center all 
the power supplies become active and are set with the same current amplitude flowing through 
the coils (if the initial position of the aggregation zone is set in the center of the pairs of coils) 
previously fabricated with the same specifications. For the aggregate to reach the targeted final 
location, a focused field setting a new aggregation zone is directed toward the new targeted 
location and is applied for a minimum period of time that is sufficient to allow the bacteria to 
reach the destination. The digital timing diagram below the figure shows the activity of each 
power supply and the relative current amplitude delivered to each coil. Then, after orienting the 
magnetic field lines towards the next location of the aggregation zone in order to avoid the MTB 
to diffuse too far from the axe separating the initial position to the next position of the aggregate, 
the aggregation zone is then set on the new target by activating all the power supplies using 
unbalanced current magnitudes in each coil to offset and localize the zero Gauss magnetic field in 
the new aggregation site. This method although simple will avoid MTB to be diffused outside the 
regions separating the two successive locations of the aggregation zone but would result in a 
distortion in the shape of the aggregate.  
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Figure 5.2. Bacteria aggregate motion control along a pre-planned path. The circle with continuous line is the actual 
position of the bacteria, while the dotted-line circle represent the target position or the bacteria in the move. 
Aggregate formation is assured by the application of a gradient magnetic field. Shutting down the power for the coil4 
result in displacement of the bacteria swarm along a funnel path. Considering the distance between the two positions 
and the mean bacteria speed, the time required for application of this field is determined. Once the time is up, the 
gradient field configuration is reapplied with unbalanced currents that cause the bacteria to aggregate in this new 
position. 
 
5.5.3 Tridimensional swarming 
The formation of the aggregate as described previously is facilitated by the presence of a 
planar obstacle such as a microscopic slide, which would most likely be the case for 
microassembly tasks. It should be noted also that the zero Gauss location could be set below the 
microscope slide at the constrained aggregation zone in order to provide sufficient directional 
magnetic field magnitude to align the MTB to achieve enhanced fluid motion for 
micromanipulation and microassembly tasks. But for other applications such as interventions 
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inside the human body, aggregate’s formation and controlled motion within a tridimensional 
space may be required. In such a case, the method described previously will not be applicable 
because the magnetic field would diverge in the z-direction (i.e. the axe previously constrained 
by the microscope slide). To overcome this limitation, a virtual magnetic barrier has to substitute 
this physical obstacle on which the MTB could accumulate. A solution to this issue is to generate 
a magnetic monopole. However, in a static magnetic field, such monopole cannot be achieved in 
a 3D volume as magnetic fields that converge from one direction will exit from the other 
direction. This limitation can be solved simply by multiplexing over time the strength and 
orientation of the magnetic field configurations to create a delimited zone in which the bacteria 
are constrained within a given aggregation zone. Figure 5.3 (a) shows the magnetic fields obtained 
when activating 5 coils, two pairs along the x- and y-axis, as well as one coil along the z-axis. In 
this configuration, the magnetic field converges towards the center of the x-y plane, while it 
diverges in only one direction along the z-axe. Figure 5.3 (b) shows the second magnetic field 
configuration when the other coil along the z-axe is activated while the first is turned off. 
Multiplexing these to magnetic field configurations in time allows the formation of an aggregate 
of MTB. Considering that the MTB are only sensitive to the direction of the magnetic field, when 
we normalize the magnetic field intensity of these two configurations at regular intervals in space 
and add them together, we obtain the configuration shown in Figure 5.3 (c). In fact, we can notice 
that some time after activating the magnetic field sequence, the bacteria will accumulate to form 
an aggregate. 
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Figure 5.3. Applying a magnetic field generated by 5 coils at a time multiplexed in order to cover all possible 
permutation resulted in a mean bacteria displacement toward the center of the coils. The time required for the 
aggregate formation using this control method is higher than formation of an aggregate in a 2D surface, because the 
applied magnetic field does not provide a direct path to the target for each instant of time. Again, powering the coils 
with unbalanced currents, cause the aggregate zone to be shifted.   
 
5.6 Tridimensional swarm control 
Figure 5.4 shows the tridimensional magnetic control of an aggregate of MTB. The 
aggregate is visible to the naked eye because of the increase in density of MTB. The MTB are 
first guided to the central plane of the sample as shown in Figure 5.4 (1) by activating both coils in 
the z-axis. The aggregate is then produced following the technique described in the previous 
section. The aggregate can then be moved along any orthogonal direction by using 5 coils. Again, 
one can observe the distortion of the aggregate caused by variations of the swimming velocities 
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among MTB in the aggregate. Such distortion can be minimized by replacing a single longer 
transition path by several shorter segments. 
 
Figure 5.4. A demonstration of bacteria control in 3D by multiplexing the power supplies over time. Powering only 
one pair of coils in a Maxwell configuration restrains the bacteria motion to a plane as depicted in (1). Photos (2) to 
(8) shows 3D control of a bacteria aggregate using the control method described in the text. 
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CHAPTER 6 TUMOUR TARGETING BY COMPUTER CONTROLLED 
GUIDANCE OF MAGNETOTACTIC BACTERIA ACTING LIKE 
AUTONOMOUS MICROROBOTS 
6.1 Introduction 
Improvement of the outcome of cancer therapy could be granted by overcoming the physiological 
barriers that a drug encounters on its way to the site of administration [9-20]. Solid tumours, 
which account for 85% of all tumours, contain heterogeneous blood vessels, which cause a non-
uniform drug distribution, and involve a high interstitial pressure that prevents drug molecules, 
particles, or cells from easily diffusing inside the tumour. Furthermore, systemically injected 
drugs are prone to bind non-specifically to healthy tissues or to be cleared by the body before a 
therapeutic effect takes place. Thus, as significant dosage of the active agent is needed in order to 
induce therapeutic effects, systemic cancer therapies cause many side effects, which are 
associated with higher systemic exposure. Existing therapies are continually improved to make 
systemic therapies more effective on tumours and less harmful to the body. The most significant 
advances are the use of active targeting [4] to ensure higher binding of encapsulated drug 
molecules on tumour cells. 
Direct drug delivery aims to restrain the cytotoxic drug effect to the tumour site. It is often 
associated with the use of drug encapsulated in magnetic particles that are steered inside the 
vasculature and delivered to the tumour using magnetic gradients [48-52]. An external power 
source in this case is required to induce a force on magnetic micro or nano-particles. Magnetic 
drug targeting is also possible using gradients field generated from a clinical magnetic resonance 
imaging (MRI) system, profiting from its imaging capabilities and integrated hardware and 
software for deep tumour targeting [58-64]. However, an autonomous microsystem capable of 
direct-targeted delivery to a specific location in the body is beyond today’s technological 
achievements. Such autonomous microsystem, if made available one day, could be similar to 
bacteria since they do have essential components for such application. Bacteria possess the ability 
to swim in low Reynolds number hydrodynamics such as the human blood flow and own a bench 
of sensors allowing them to react to specific stimuli in addition to their ability to produce and 
synthesize molecules and toxins.  
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Many sorts of bacteria, like Clostridia, Salmonella and Bifid bacterium, accumulate preferentially 
in tumours [67-74]. They have been considered as potential candidates to fight cancer because of 
their ability to reach hypoxic regions of solid tumours, which are hard to target with conventional 
therapies. Clostridium novyi, obligate anaerobic bacteria, causes signiﬁcant xenograft tumour 
regression in mice when administered in combination with chemotherapy and an antivascular 
agent [69]. They are found to successfully germinate in the hypoxic parts of the tumour. While C. 
novyi have been depleted from their lethal toxin prior to intravenous injection, Salmonella 
typhimurium are proven to be better tolerated by the body at high dose as demonstrated by initial 
clinical trials [81]. Presence of quiescent and necrotic cells is found necessary for the 
accumulation of S. typhimurium in the central region of cylindroid polycarbonate lids, which 
suggests a minimum tumour size is required for bacterial therapy usability. Bifidobacterium 
adolescentis, normal inhabitants of healthy human and animal intestinal tracts, have also been 
used as the delivery system to transport endostatin genes to solid tumours. Once more, trials on 
tumour bearing mice revealed the presence of this bacillus only in the tumour, sparing normal 
tissues. 
The foundation of the bacterial cancer therapy goes back to the pioneering work of Dr. Coley 
who was among the first to deliberately induce a bacterial infection in final stage patients to treat 
cancer [66]. Even though the preferential replication and accumulation of many bacteria in 
tumours was proven since then, bacteria cancer therapy faces many challenges before it becomes 
clinically effective. The first major limitation is the necessary high dose required to induce a 
significant therapeutic effect, which is most of the time associated to severe toxicities. The 
inefficiency of bacteria to target small tumours, where a hypoxic zone is not formed yet, 
constitutes the second major limitation. Also, combining bacterial therapy with other 
conventional methods, such as chemotherapy or radiotherapy, is mandatory in most cases for 
complete tumour consumption.  
In order to take profit from the capability of the bacteria to reach the hypoxic zone of tumours, 
systemic administration and bacterial attraction to the tumour must be optimized. We propose to 
use magnetic fields to guide the bacteria to tumours instead of chemotaxis and aerotaxis, which 
are the conventional ways bacteria use to invade the tumour. Magnetotactic bacteria (MTB) 
orient and swim following the direction of an applied magnetic field [46, 82-84]. We propose to 
use them as remotely computer-controlled drug transporters. We demonstrate in this paper that a 
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significant tumour invasion and penetration can be achieved through direct navigation by 
magnetic fields of MTB. 
6.2 Materials and methods 
6.2.1 MC-1 magnetotactic bacteria 
MC-1 strain was chosen for the in vivo experiment due to its high motility speed, appropriate size 
and its magnetotactic ability. At the difference of the bacteria that proliferate in the tumour, the 
MC-1 cannot reproduce and grow at 37 degrees. In fact, at 37 degrees, its speed decreases from 
180µms-1 to 20µms-1, 40 minutes after its exposure, time after which the bacteria die. Not only 
the temperature affects MC-1 MTB swimming speed, the channel diameter also has an effect. It 
is found experimentally that the speed of MC-1 MTB goes from 180µms-1 in open space to 
120µms-1 inside a 4µm channel. MC-1 synthesizes Fe3O4 magnetic nanoparticles, called 
magnetosomes that it assembles into a chain that acts as a compass forcing the bacteria to align 
with an applied magnetic field. When the magnetosomes size is optimized for maximum 
magnetic field sensitivity, MC-1 becomes sensitive to magnetic fields as low as 0.3 Gauss. 
6.2.2 Animal tumour model 
MDA-MB-231, a breast cancer human cell line, was injected s.c. on each flank of nu/nu 7 CD1 
female mice. After tumours growth, MTB navigation experiments started. A 100µl of 1x108 
MTB/ml in PBS was injected in the trail vein of the animal. Depending on the magnetic 
treatment and the MC-1 injection, four groups were discerned. The first group (group I) was a 
control that lacked a MTB injection and an applied magnetic field. The second group (group II) 
was also a control group that received a MC-1 injection but lacked the applied magnetic field. 
The third group (group III) was an experimental group that received a MC-1 injection and a 
where a magnetic field was applied to target the tumour. An electromagnet was used for MC-1 
guidance for group III.A, while 3D coils were used for group III.B. The magnetic field was 
applied for 30 minutes, then the animal was sacrificed and the tumours, liver, spleen, and kidney 
were extracted for immunohistochemistry analysis. 
Two tumours, one on each flank, were grown in mice belonging to the group III. One tumour 
served as a target, while the second was a control. Comparisons between tumours from the 
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different groups and tumours belonging to the same mouse were done in order to assess the 
magnetic advantage over passive targeting. Table 6.1 presents a summary of the experimental and 
control groups used for the experiments.  
 
Table 6.1. Description of the groups used in the in vivo experiments.  
GROUPS MC-1 
INJECTION 
Magnetic field 
application 
NUMBER OF 
TUMOURS 
PER MOUSE 
DESCRIPTION 
Group I (1 mouse) No No 1 
Control group used to assess the validity of the 
immunohistochemistry coloration. In the text we refer to this group 
as a negative control group. 
Group II (2 mice) Yes No 1 
Control group used to estimate the magnetic advantage over passive 
targeting. In the text we refer to this group as a positif control group. 
Group III.A (2 mice) Yes Yes 2 
Experimental group. Magnetic field generated with an electromagnet 
(similar to a permanent magnet). The magnet was placed externally 
to the tumour. 
Group III.B (2 mice) Yes Yes 2 
Experimental group. Magnetic field generated with a tridimensional 
coils system. The magnetic field was focused on the center of the 
tumour. 
 
 
6.2.3 Magnetic setups 
Two different magnetic setups are used; the first one consists on an electromagnet placed on the 
targeted tumour and powered by a current source delivering a magnetic field of 20 Gauss on its 
tip. The magnetic field is estimated to be 15 Gauss in the center of the targeted (primary) tumour 
and 3 Gauss in the center of the secondary tumour. The second setup consists on three orthogonal 
magnetic pairs of coils capable of generating a focused magnetic field on the target, as shown in 
Figure 6.1. In this case, the magnetic field is zero in the center of the targeted tumour. The non-
targeted tumour was positioned inside the setup so that there is less magnetic targeting, which 
was not the case with the electromagnet since a guiding magnetic field on the secondary tumour 
was present but having lower intensity.  
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Figure 6.1. Magnetic field simulation showing the magnetic field lines as generated by (a) a 3D magnetic 
coils system and (b) an electromagnet or a permanent magnet. The magnetic field in (a) is focused on the 
target, and thus the bacteria will be attracted to the center of the tumour. However, in (b), the bacteria are 
attracted to the electromagnet tip. 
 
6.2.4 Immunohistochemistry and images analysis 
Tumours and collected organs were fixed in a 10% formalin solution for immunohistochemistry 
analysis. A longitudinal section of each tumour was coloured to highlight the MC-1 distribution. 
In the immunohistochemistry slides, we could identify a MC-1 bacterium as a 1 to 2µm-sized 
coccus with a yellow to brown color. Bacteria were counted using the Cell Counter plugins of the 
ImageJ software (Wayne Rasband, National Institutes of Health, USA).  
 
!" #"
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6.3 Results 
6.3.1 Organs and blood analysis 
Following the i.v. injection, we found MC-1 bacteria in the liver, the spleen, the tumour, and the 
blood. Figure 6.2 shows two histology slides of the spleen and the liver. The bacteria are 
recognized by their brown color, circular shape and characteristic size. They have been found to 
accumulate in the liver and the spleen but we did not find any in the kidney. Analysis of blood 
samples at the end of the experiment revealed the presence of MC-1 in a normal motile state. In 
fact, because the animal was under anesthesia, the temperature of the body decreased which 
increased in its turn the in vivo lifetime of the bacteria. 
 
Figure 6.2. Immunohistochemistry coloration of a section of the spleen and the liver displaying the presence of MC-
1. 
 
6.3.2 Comparison between the control groups and the experimental groups 
The group I tumour that did not receive any treatment was analysed in order to confirm the 
specificity of the antibody used for the immunohistochemistry. Very few unspecific reactions 
were noticed for the group I, which can be explained by antibodies binding to some cellular 
debris. Meanwhile, when compared to groups where a bacteria injection was carried out, the 
number of wrong signals found was up to 38 times less. Table 6.2 summarizes some key data for 
!"#$$%& '()$*&
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the in vivo experiments.  We counted the number of bacteria in two histology slides for each 
tumour. Table 6.2 also displays the higher density of the bacteria that was observed inside a FOV 
of 100µm2, and the invaded surface of the tumour with more than 20 MC-1 cells per area of 
100µm2. Figure 6.3 shows in a graphic bar the number of MC-1 cells found in tumours for each of 
the 4 groups. Tumours of the group III.B were the most targeted showing the highest number of 
bacteria in the histology slide. Also, this group exhibited the highest observed bacteria density. In 
fact, the area, containing a cell density of more than 20 MC-1 per 100µm2, was more than twice 
as big as the one observed for the groups II and III.A.  
A color map graphic showing the distribution of the MC-1 cells in the tumour is depicted by 
Figure 6.4. We notice a higher presence of MC-1 in the center of the tumour for the group III.B 
where the bacteria accumulated in large quantity. A histology portion shows an example of a 
highly invaded section of the tumour’s centre belonging to the group III.B.  
Table 6.2. Summary of the key data obtained after histology slide analysis for the control and the experimental 
tumours.   
TUMOUR  TUMOUR SURFACE 
(mm2) 
MEAN NUMBER 
OF BACTERIA 
MAXIMUM DENSITY 
(NUMBER OF MC-1 
IN 100 µm2) 
INVADED SURFACE* 
(mm2) 
Group I  182  24 4 0 
Group II  
124.5 205 40 0.41 
105.5 618 37 0.88 
Group III.A  
150 312 55 0.53 
72.1 344 70 0.80 
Group III.B  
85 905 95 2.28 
185 914 54 1.47 
* 
Only a density of more than 20 MC-1 in 100 µm2 was considered 
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Figure 6.3. Graphic bar showing (up) the number of bacteria found in tumours for the 4 groups and (down) the 
invaded surface where a density of more than 20 MC-1 cells per 100µm2 was found. 
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Figure 6.4. In vivo MTB targeting experiment. MDAMB-231 tumour cells were grown in the flanks of nu/nu CD1 
female mice. After MTB intravenous injection, a magnetic targeting procedure using an electromagnet (group III.A) 
and a 3D coils system (group III.B) was applied. An immunohistology analysis of the tumours reveals the presence 
of MTB in the necrotic region. The MTB exhibit a particular color as well as a characteristic size and shape which 
allow their differentiation it from the xenograft cells. A color map of the four experimental tumours groups is shown. 
The color corresponds to the bacterial count inside a FOV of 100µm2. We notice a wider distribution of MTB in the 
group III.A and group III.B compared to the group II. In fact, in group III.A and group III.B a magnetic guidance 
was imposed while for the group II only the blood flow is responsible for the delivery of MTB to the tumour. 
 
6.3.3 Comparison between tumours from the same mouse 
The experiment that most highlights the magnetic advantage over passive bacteria transport is the 
one involving comparison between tumours implanted in the same mouse with the magnetic field 
focused on one tumour but not on the other. Table 6.3 presents the surface of the tumour’s section 
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and the number of bacteria that were found. Tumours belonging to the group III.B, which 
received a magnetic control using the 3D coils system, depict a number of bacteria in the targeted 
tumour that is 10 times larger than its counterpart in the non-targeted one. However, there is no 
clear indication whether or not there is a magnetic advantage in using the electromagnet for MTB 
delivery to tumours. Figure 6.5 shows the number of bacteria in the targeted and in the non-
targeted tumours in a graphic bar for groups III.A and III.B. 
Table 6.3. Summary of the key data obtained after histology slide analysis for the tumours implanted on the same 
mouse. 
TUMOUR GROUP TUMOUR SURFACE  
(mm2) 
NUMBER OF 
BACTERIA 
Group III.A  
Targeted Tumour 150 312 
Non-targeted Tumour 53.9 34 
Targeted Tumour 72.1 344 
Non-targeted Tumour 93.5 700 
Group III.B  
Targeted Tumour 85 905 
Non-targeted Tumour 105 28 
Targeted Tumour 185 914 
Non-targeted Tumour 70.4 145 
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Figure 6.5. Graphic bar showing the number of MC-1 cells for the tumours implanted on the same mouse. Each 
pair of bars represents respectively the non-targeted and the targeted tumour for one mouse. This experiment has 
been conducted only for the group III.A and group III.B. A higher magnetic targeting specificity is obtained with 
the 3D magnetic coil systems rather than the electromagnet. 
 
6.4 Discussion 
The in vivo results presented in this paper constitute a preliminary investigation on using 
magnetotactic bacteria to target tumours. As it was reported in the past with other bacteria types, 
the magnetotactic bacteria were able to reach deep tumour regions often characterized by necrosis 
and hypoxia. A special magnetic system, which was designed and built especially for these in 
vivo experiments, helped the accumulation of the bacteria in the tumour through the application 
of a focused magnetic field on the target. In this paper, we report on average twice the number of 
bacteria found in the tumour when a magnetic field was applied using the 3D magnetic coils 
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system over passive transport with the blood flow in the absence of any magnetic field. A second 
experience based on the comparison of tumours implanted in the same animal reported 10 times 
more bacteria in the targeted tumour over the non-targeted tumour. This result suggests that the 
applied magnetic field may also be used to avoid a specific zone in the body. 
After being injected in the blood stream, the bacteria are transported by the flow, and since the 
tumour is highly vascularized, especially in the periphery, we naturally expected to find bacteria 
without the application of a magnetic field. In fact, finding bacteria in deep tumour regions 
highlights the advantage of the bacteria active motility and its effective molecular motor over 
passive targeting. 
To avoid systemic circulation, magnetotactic bacteria can be used for localised delivery of 
therapeutic drugs to solid tumours. However, small animal tests do not allow the reproduction of 
a localised delivery experiment, as projected in the future. Ideally, the bacteria have to be injected 
as near as possible to the tumour site, or in its periphery. In this case, tumours that are accessible 
through natural means, such as colorectal cancer, become more attractive candidates for this kind 
of drug delivery.  
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CHAPTER 7 DESIGN OF A MTB-BASED SYSTEM FOR HUMAN                      
CANCER TREATMENT          
7.1 Introduction 
This section presents the overall robotic platform responsible for MTB drug delivery. Aside from 
the computer controlled magnetic coils system responsible for MTB navigation, magnetic 
resonance imaging will be used for operation monitoring and road map evaluation.  
7.2 Platform design 
The future robotic platform that will encompass MTB drug delivery is built around a modified 
magnetic resonance imaging (MRI) system that will provide MTB navigation, body imaging, and 
emboli particle steering. The MTB navigation is granted by a set of magnetic coils, similarly 
described in chapters 4 and 5, that will be placed outside of the MRI bore. In fact, the high static 
magnetic field of the MRI prevents the use of the MRI as well as its gradients for MTB 
navigation because it is not possible to change the direction of the magnetic field inside the MRI. 
The 3D Steering Magnetic Coils (SMC), represented in Figure 7.1, will be connected to the MRI 
bore through the patient table. This table will be placed inside the MRI for imaging and inside the 
SMC for MTB navigation.  The imaging capabilities of the MRI will be used for the road map 
sketch, target imaging as well as quantification of targeting success at the end of the procedure. 
The procedure will theoretically end when the bacteria are considered dead, about after 30-45 
minutes after MTB injection). The MTB targeting methodology is as follows:  -­‐ Tumour imaging and road map sketch. (Using MRI) -­‐ Injection of the MTB loaded drug and guidance to the tumour site based on a vasculature 
model of the tumour (outside the MRI, inside the magnetic field control coils). -­‐ Imaging and quantification of targeting success using MRI images by comparing them to 
the ones taken before injection. The percentage of MTB reaching the tumour can be 
obtained using calibration curves representing the MR-relaxation rate for different MTB 
concentration. 
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Although the bacteria approach would perform better than any other in the low Reynolds 
hydrodynamic environment of the capillary network, their limited thrust would not be able to 
counteract the greater flow rates encountered in larger diameter blood vessels. For this reason, 
emboli particles can be used to obstruct the blood vessels supplying the tumour with a technique 
known as Magnetic Resonance Propulsion (MRP) discussed in the first chapter of the literature 
review. The coils responsible for the navigation and steering of the magnetic emboli particles are 
denoted as SGC on the Figure 7.1. 
 
Figure 7.1. Robotic platform depicting the MRI bore in which lies 3D Steering Gradient Coils (SGC) aimed to propel 
emboli magnetic particles. Facing the MRI bore, the 3D Steering Magnetic Coils (SMC) are responsible for MTB 
guidance and delivery to the tumour. The MRI table moves the patient from the inside of the MRI to the SMC. The 
magnetosomes inside the MTB cause signal loss on MR-images that allows, with the help of a proper calibration 
curve, the evaluation of the percentage of bacteria that reach the target. 
7.3 Magnetic Resonance Imaging of MTB 
Magnetic nanoparticles have been used for a long time as contrast agents for Magnetic 
Resonance Imaging (MRI). Depending on the size of the nanoparticles, the contrast agents are 
classified as SPIO (superparamagnetic iron oxides) for nanoparticles of diameters greater than 
50nm or USPIO (ultra-small superparamagnetic iron oxide) for those of diameters less than 50nm 
[122-124]. Even though their effect on the MR-image is different, both SPIO and USPIO rely on 
the magnetic susceptibility difference to their surroundings to create strong local magnetic field 
heterogeneities. 
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Besides their usage as contrast agents, superparamagnetic nanoparticles are used for cell-labeling 
prior to in vivo injection [125]. In fact, nanoparticles used for labeling are uniformly distributed 
and are attached to the cells via antibody binding. These nanoparticles alter the MR-signal 
because of their effect on the magnetic field. In the case of MTB, the nanoparticles are embedded 
in the bacterial cells rather than being attached to the cell membrane. 
7.3.1 Magnetosomes effect on MR-signal 
MTB synthesize magnetosomes in a permanent single domain size range. The particles are then 
uniformly magnetized with maximum magnetic dipole moment per unit volume [100]. The 
induced magnetic field from a single magnetosome can be approximated by the field of a dipole 
as described by Equation 7.1 where µ0 = 4π10-7 H·m-1 is the permeability of free space.  
!
B ' P( ) = µ04! 3
!m. !r( ) !r
r 5
!
!m
r 3
"
#
$
$
%
&
'
'
 (7.1) 
For a uniformly magnetized object, the dipolar magnetic moment m

(A·m2) is given by  
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where 
!
M
SAT
 is the saturation magnetization of the object, and a, its radius (m) if its shape is 
approximated as a sphere. Not only does the size of the magnetosomes contribute to the total 
magnetic dipole moment (the sum of the moment of the individual particles), but their 
arrangement along a chain does as well. Figure 7.2 shows a numerical simulation of the magnetic 
field lines induced by a magnetosome chain superimposed on top of an image of a MC-1 
magnetotactic bacterium. Typically, there are 5 to 14 magnetosomes per cell with sizes averaging 
between 70 and 100nm. For our simulation, we consider a chain of 11 magnetosomes in length 
with a mean magnetosome diameter of 80nm. The saturation magnetization of magnetite is 0.6 
Tesla. 
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Figure 7.2. Magnetic field lines generated by a magnetosome chain superimposed on top of an image of a 
magnetotactic bacterium. In this simulation, we consider the presence of 11 magnetosomes with a mean diameter of 
70nm. The distance between the magnetosomes is of 20nm. The saturation magnetazation for magntite (0.6 Tesla) is 
considered since at the MRI field of 1.5 Tesla, the magnetite chain is saturated. 
The magnetosome chain will significantly disturb the local magnetic field. As depicted in Figure 
7.3, the magnetic field perturbation is significant near the bacterium surpassing 100ppm and 
decreases farther away from the bacterium. This is quite significant for our application 
considering that an accepted homogeneity level of modern MRI clinical scanner is approximately 
5ppm over a 50cm diameter spherical volume at 1.5Tesla. On a macroscopic scale, these 
perturbations will cause geometric as well as intensity-based artifacts. However, on a 
microscopic scale, these perturbations will affect the spin-lattice (T1) and spin-spin (T2) 
relaxation times as given by 
[ ];11
0,
MTB
TT iii
α+=  i =1,2  (7.3) 
where ,0iT is the relaxation rate of the medium, [ ]MTB  is the concentration of the magnetotactic 
bacteria (cells/ml) and iα  is the relaxivity expressed in (
ml
cells s⋅
) a property specific to the effect 
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of MTB on the NMR signal. Equation 7.3 is generally used to characterize contrast agents in an 
MRI. 
 
Figure 7.3. Simulation of a local magnetic field perturbation for a uniformly distributed concentration of MTB. The 
distance between MTB is taken to be 25µm, which corresponds to a concentration of approximately 107 bacteria/ml. 
7.3.2 Relaxation times 
Several concentrations of MTB were prepared by centrifugation. Qualitative observation of 
bacterial motility and response to a magnetic field before and after concentrations through 
centrifugation was performed using a Zeiss Imager Z1 microscope. Each concentration of the 
bacteria samples was determined by direct counting and by optical density measurements as 
presented in Table 7.1. Each 1ml MTB sample used for the experiments was inserted into a 2ml 
Progene microtube. 
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Table 7.1. Bacterial concentration and T2-relaxation values for different MTB concentrations calculated from signal 
ratio measurements. 
 
 
Images were run under a Siemens Avanto 1.5Tesla scanner using a wrist antenna. T1-weighted 
spin echo sequence parameters were: TE = 11ms with three different TR = 450/550/700ms, slice 
thickness of 20mm, and pixel spacing of 0.586 mm. T2-weighted fast spin echo sequence 
parameters were: TE = 96/125/135ms, TR = 5096ms and pixel spacing of 0.293mm. 
Samples containing MTB show signal enhancement compared to the medium in T1-weighted 
images as depicted in Figure 7.4. However, this signal enhancement does not change much with 
higher MTB concentrations. The effect of the concentration of MTB is more evident on T2-
weighted images as depicted in Figure 7.5. As the concentration of bacteria increases, the signal 
decay becomes important. Table 7.1 presents T2-relaxation values calculated from signal ratio 
measurement with different TE values. Figure 7.6 shows the signal variation as a function of the 
bacteria concentration for different TE values. As the TE value increases, the difference in signal 
between different concentrations increases as well. Using Equation 7.3, we can calculate the T2-
relaxivity for MTB, this value is found to be 82 7.448 10 ( )
ml
cells s
α −= ⋅
⋅
. Once the relaxivity of an 
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agent is known, the concentration of the MTB can be obtained on a voxel basis by direct 
measurement of the T2-relaxation value and inversion of Equation 7.3. 
 
Figure 7.4. T1 images of several concentrations of magnetotactic bacteria (MTB) samples. Samples 1 to 6 (as 
numbered in a) show increasing concentrations starting with a medium without MTB (sample 1). T1-weighted spin 
echo sequence with TE = 11 ms, three different TR = 450/550/700 ms, a slice thickness of 20mm, and a pixel spacing 
of 0.586mm. (b) Signal intensity as a function of bacterial concentration for a T1-weighted acquisition with three 
different Repetition Time (TR) values. Notice that the signal contrast between samples of different concentrations is 
not important. 
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Figure 7.5. T2-images of several concentrations of magnetotactic bacteria (MTB) samples. Samples 1 to 6 (as 
numbered in a) show increasing concentrations starting with a medium without MTB (sample 1). T2-weighted fast 
spin echo sequence with TR = 5096ms, three different TE = 96/125/135ms, a slice thickness of 20mm, and a pixel 
spacing of 0.293mm. (b) Signal intensity as a function of bacterial concentration for a T2-weighted acquisition with 
three different Echo Time (TE) values. Notice that the signal contrast between samples of different bacterial 
concentrations is important. 
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Figure 7.6. T2-relaxation curves for different MTB concentrations. 
Hence, MTB cause a decrease in both T1 and T2 values in a manner inversely proportional to 
their concentration; however, the effect on T2 is found to be greater than the effect on T1 as is the 
case with superparamagnetic MRI contrast agents. In fact, the magnetosome chain will cause in 
this case a decrease in signal intensity and rapid signal decay through T2 enhancement. This 
attenuation of the signal is proportional to the concentration of bacteria and allows for 
quantification and guiding of MTB by magnetic control. Previous studies on bacterial analysis 
and quantification in MRI have reported the possibility to detect concentrations of 108-109 
cells/mL of magnetically labeled bacteria [123]. We were able to detect MTB at a concentration 
as low as 2.2×107cells/mL using a clinical MRI scanner in a field of 1.5 Tesla. 
7.3.3 Separation and evaluation of different sources of contrast 
In order to verify and prove that the magnetosomes are the main source of the contrast seen on T2 
MR-images, we separately investigate the influence of the magnetosome’s chain, the motility, 
and the cell of MC-1 magnetotactic bacteria (MTB) on the Magnetic Resonance imaging (MRI) 
contrast. Three samples were used. The first sample is made up of magnetic bacteria that 
successfully synthesize magnetic nanoparticles. MC-1 bacteria that do not synthesize 
magnetosomes form the second sample while the third sample is composed of dead MC-1 
magnetic bacteria. T2-weighted magnetic resonance images were obtained for multiple echo 
times.  
The MC-1 cell itself, when no magnetosomes are synthesized, seems not to have any noticeable 
effect on MR-images. In fact, Figure 7.7 shows T2 experimental relaxation curves for magnetic and 
  89 
 
non-magnetic MC-1 cells as well as the medium. As TE values are increased, the signal intensity 
for the magnetic MC-1 dropped while the one for non-magnetic MC-1 did not change when 
compared to the medium. While the T2 value for the magnetic MC-1 was estimated to be 203ms 
for a bacterial concentration of 5⋅107 MTB per ml, it was found to be 725ms for the non-magnetic 
MC-1. The PBS medium has an experimental T2 equal to 1072ms. Experimental T2 relaxation 
curves for motile and non-motile magnetic MC-1 show very slight differences as depicted in 
Figure 7.8. At the same bacterial concentration of 1⋅108 MC-1 per ml, the T2 value for the motile 
MC-1 was estimated to be 162ms while it was estimated to be 148ms for the non-motile MC-1.  
 
Figure 7.7. Experimental T2 relaxation curves for magnetic and non-magnetic MC-1. The signal variation of the non-
magnetic MC-1 is very similar to the medium. While the T2 value for the magnetic MC-1 was estimated to be 203ms 
for a bacterial concentration of 5⋅107, it was found to be 725ms for the non-magnetic MC-1. The PBS medium has an 
experimental T2 equal 1072ms. T2 was estimated by fitting the signal intensity data for different TE values to a 
monoexponential decay curve. 
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Figure 7.8. Experimental T2 relaxation curves for motile and non-motile MC-1. Both samples show similar 
relaxation curves. An identical bacterial concentration of 1⋅108 MC-1 per ml was used for both samples. The T2 value 
for the motile MC-1 was 162ms while it was 148ms for the non-motile MC-1. T2 was estimated by fitting the signal 
intensity data for different TE values to a monoexponential decay curve. 
From Figure 7.7 and Figure 7.8, we conclude that the MR-contrast obtained in the presence of MC-1 
is mainly due to the presence of magnetic nanoparticles inside the cell body. The cell constituent 
and the motion add very little to the MR-contrast. 
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CHAPTER 8 GENERAL DISCUSSION 
 
The use of magnetotactic bacteria, in particular MC-1 cells, can enhance tumour-targeting 
efficacy compared to the use of magnetic microparticles when traveling through the smallest 
diameter capillaries found in the human microvasculature. On the other hand, the use of magnetic 
microparticles, especially with materials of relatively high magnetization saturation, becomes 
more effective in larger diameter capillaries when compared to the use of the MC-1 cell as 
microcarriers for targeted drug delivery. 
The discussion section comprises a comparison of targeting efficiency with magnetic 
microparticles and with MTB, emphasizing the particularities of each method. 
8.1 MTB vs magnetic microparticles: yield comparison in drug delivery to 
tumours  
Prior to comparing drug delivery to tumours using MTB and magnetic microparticles, an 
understanding of the fundamental theoretical equations used to compute the efficiency of each 
approach is necessary. In fact, the mathematical laws governing motion of magnetic 
microparticles in the microvasculature differ from those for magnetotactic bacteria. 
8.1.1 Magnetic force on a magnetized particle 
A magnetic particle being transported by the blood flow in the microvasculature still needs to be 
steered at vessel bifurcations for enhanced targeting. Steering in this particular case is 
accomplished using a magnetic force Fmag (N) that acts on a magnetized body and that is induced 
by a gradient field H (A·m-1). Such force is computed as 
 (8.1) 
where m (A.m2) is the magnetic moment and µ0 (N.A-2) is the permeability of vacuum. A 
spherical magnetic particle with a radius R (m) subject to a magnetic force will move with a 
velocity 
HmFmag
 )..(0 ∇= µ
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 (8.2) 
where η (Kg.s-1.m-1) is the viscosity of the medium.   
Magnetic microparticles compete well against MC-1 cells if the velocity computed in Equation 
8.2 is equivalent or greater than the swimming velocity of MTB in human blood as recorded 
experimentally. Although our group has recorded average and peak swimming velocities of 
approximately 200 and 300µm·s-1 respectively in human blood at room temperature, we 
considered, for the sake of comparison, an average swimming speed of υ0 = 100µm·s-1. This 
decision was taken in consideration of our experimental results, which showed that the velocity 
of the MC-1 cells decrease continuously when operating at the human internal temperature of 
37oC and reach a maximum operational time of approximately 40 minutes. 
8.1.2 MTB alignment with an external magnetic field 
The chain of magnetosomes inside the cell will contribute to maximize the magnetic moment of 
each bacterium where the ratio between the thermal energy and the magnetic potential energy can 
be expressed as 
 (8.3) 
We notice here that a higher value of H is required to maintain the orientation of the MC-1 cell in 
order to correct displacement error. This error is caused by an increase of Brownian motion due 
to the higher temperature level in the microvasculature. Hence, as given in [83], the average 
value of cos ϕ is found to be 
 (8.4) 
For a cell with a magnetic moment m of 10-16(A.m2) at room temperature (297.15oK), the 
magnetic energy is 1.15 times the thermal energy when subjected to the geomagnetic field of 
0.5Gauss. However, an increase of the magnetic field to 4 Gauss will yield very accurate 
displacement with an energy ratio of approximately 10. 
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If we neglect thermal fluctuations and a high enough external magnetic field H, the dynamics of 
the orientation of the bacterial magnetic moment with the magnetic field can be determined using 
Equation 8.5 [104]. 
 (8.5) 
In Equation 8.5, α is the rotational friction coefficient, θ is the particle orientation with respect to 
a fixed direction, and β is the angle between the magnetic field and the magnetic moment of the 
cell.  
This comparative study includes several morphotypes of MTB that exist in nature. Commonly 
observed morphotypes include spherical cells (cocci), rod-shaped, curved bacteria (vibrio), multi-
cellular MTB (a group of cells arranged as a sphere), and helical (spirillum) of various 
dimensions and swimming velocities. 
8.2 Comparative study contextualize 
Even though many factors influence the motion of microparticles and MTB in the 
microvasculature as described in [49], we only consider here the most predominant factors: the 
magnetic and fluidic forces. The fluidic force is caused by the blood flow and is equal to 
 (8.6) 
Equation 8.6 considers a laminar flow and a spherical particle having a hydrodynamic radius of 
RP. In Equation 8.6, η and υf  are the blood viscosity and velocity respectively. Here, equilibrium 
of forces between magnetic force and Stokes law of fluid friction weighted by a wall effect 
correlation [126] allows us to calculate the theoretical particle magnetophoretic terminal velocity 
[127] inside a microchannel. 
Considering a simple navigation case consisting on a Y-shaped microvascular channel as 
depicted by Figure 8.1, the targeting efficiency is assessed for different steering parameters for 
both magnetic microparticles and MTB involving various flow rates and sizes of microchannels 
as to reflect real conditions in the human vasculature. 
sin 0d mB
dt
θ
α β− + =
( )6f P P fF Rπη υ υ= − −
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Figure 8.1. Y-shaped microvascular channel used for navigation simulation of steering efficiency. D represents the 
channel diameter and L its length; we consider L = D × 100. Even if magnetic particle steering involves many forces, 
we consider only the most important, which are the magnetic and fluidic forces. MTB are subject to magnetic torque, 
but their motion is governed by flagella, which allow the bacteria to move at constant speed along the direction of the 
magnetic field. 
In this study, the velocity of MC-1 cells is compared to the velocity of a 2µm magnetite sphere 
steered by magnetic gradients in the blood. Magnetite is a well-known material with a relatively 
high magnetization saturation and proven biocompatibility. This material is widely used as a safe 
contrast agent for MR-imaging. 
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 The channel taken from realistic conditions has a length-diameter ratio of 100 or in other words, 
L = D×100 where L is the channel length and D is the diameter. For every channel diameter, we 
calculated the maximum blood flow that allows for 100% steering efficiency. In order for a 
microparticle or MTB to be steered toward the targeted channel at the bifurcation, it was assumed 
that half the diameter of the main channel had to be traveled before reaching the bifurcation. This 
was considered as a worst-case scenario since all the microparticles located on the same side of 
the centerline of the channel prior to the Y-bifurcation were to exit through the targeted outlet. 
Table 8.1. Summary characteristics of some MTB and calculation of the required gradient  necessary to have a 
magnetophoretic speed equivalent to the MTB speed giving a spherical magneitte microparticle with the same size 
range as the MTB.  
 
MTB  NAME CELL 
MORPHOLOGY 
Mean Speed 
(µm·s-1) 
WIDTH (OR 
DIAMETER) 
(µm) 
LENGTH 
(µm) 
MAGNETIC MICROPARTICLE 
DIAMETER 
(µm) 
MAGNETIC GRADIENT  
(mT·m-1) 
MC-1 [44] Coccoid 200 2 - 2 7.6×103 
Magnetospirillum 
gryphiswaldense [85] 
Helical 50 0.2–0.7 1-20 10 91 
AMB-1 
[86] 
Helical 49 0.5 3-10 5 320 
MV-1 and MV-2 
[87] 
Vibroid to 
Helical 
-* 0.2–0.5 1-5 2 1.9×103 
MMP (Many celled 
Magnetotactic 
bacteria)[87] 
Sphere (a 
cluster of 10-
30 Coccoid 
cells) 
105 3-12 - 8 287 
Magnetobacterium 
bavaricum [87] 
Rod-shaped 40 1–1.5 6–9 7 139 
RS-1[87] 
Helical to 
Rod-shaped 
-* 0.9–1.5 3-5 4 326 
Magnetospirillum 
magnetotacticum 
(MS–1) [88] 
Spirillum 40 0.5 5 2.5 989 
* For MTB speed missing data we considered a value of 50 µm·s-1 for the calculation of the magnetic gradient 
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8.3 Comparative study simulation results 
Table 8.1 summarizes the main MTB characteristics such as their cell morphology, respective 
swimming velocity and dimension. It also displays the magnetic gradient required to move a 
magnetite microparticle of similar size at the same velocity as the corresponding cell type’s 
velocity. The smaller the cell is, the higher the required magnetic field must be in order to 
achieve the same velocity (specify). In fact, for some cases like those of MC-1, MV-1, MV-2 and 
MS-1 cells, the magnetic gradient required to achieve an equivalent speed is extremely high and 
may even be impractical for deep targets in the human body. For smaller MTB with relatively 
low swimming speeds, the required magnetic gradient is reasonable and could easily be 
implemented. However, these smaller MTB would not necessary be good candidates to target 
tumoural lesions. The use of molecular motors embedded in MC-1 magnetotactic bacteria for 
drug targeting is an efficient method since it does not require an external energy source. On the 
other hand, despite its limitations in the smallest diameter capillaries, magnetic drug targeting 
represents a more flexible approach where steering parameters can be customized depending 
upon the application needs and the geometry of the targeted vessels. Another interesting feature 
in the use of MTB is the fact that they do not require blood flow to move. This facet allows them 
to swim in larger diameter vessels if complemented by another method, such as the use of a 
balloon catheter or larger magnetic embolization particles to temporarily stop blood flow. These 
cells can also be very effective in enhancing the uniform distribution of drugs inside the tumour, 
which is a key component to the eradication of the tumour. Furthermore, MTB can increase the 
time required for drugs to be in direct contact with cancerous cells because of the high interstitial 
pressure inside the tumour. Without the use of MTB, the diffusion of drugs would otherwise be 
very slow. 
High gradient amplitudes are required to achieve 100% steering efficiency with moderate flow 
velocities. For instance, the MC-1 cell can theoretically sustain a flow rate of 10mm·s-1, which 
would require gradient amplitudes as high as 2T·m-1 for a magnetite microparticle of the same 
diameter as the MC-1 cell. Hence, to reach a higher magnetophoretic velocity, a smaller particle 
must be submitted to a much higher magnetic gradient than a larger particle containing a higher 
effective volume of the same magnetic material. The magnetic force in this case is greatly 
affected by the size of a spherical magnetic core since such force will be proportional to the cube 
of the radius of the core itself. 
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In fact, larger magnetic cores with diameters of 5µm or higher can be used not only for targeting 
in the tumour itself, but for embolization of small capillaries near the tumoural lesion in order to 
stop blood supply to the tumour. The maximum flow velocity within which 100% steering 
efficiency of microparticles of 5µm can be achieved is much higher than that required for 2µm-
wide magnetic microparticles, even with relatively moderate magnetic gradients (<0.5T·m-1). We 
notice that in this case, MC-1 MTB is no more efficient a solution compared to magnetic 
microparticles that can sustain a large flow velocity with reasonable magnetic gradients. In 
addition to an increase in particle size, other magnetic components that present higher 
magnetization values than magnetite, such as Cobalt-Iron, could also be used to increase the 
magnetic force and achieve higher magnetophoretic velocities. Such models are possible 
provided that the design prevents the release of toxic Cobalt ions in the blood. 
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CONCLUSION 
Magnetotactic bacteria were investigated as drug delivery vehicles to solid tumours. They exhibit 
the advantage of being controllable by magnetic field, which in its turn, can be generated by a 
computer program.  
In order to develop this new concept, fundamental studies on the bacteria’s motion, its response 
to different magnetic field values and relaxation parameters in MRI were conducted. Then, 
magnetic navigation was investigated keeping the main final application of active delivery of 
drug to tumours in mind. Designing a magnetic setup that is adapted to a human body was also an 
issue that influenced the final platform design. Finally, the real question was to see if the MC-1 
bacteria could indeed target deep inside tumours in a live animal. We validated that the MTB 
could target tumour cell xenografts grown in the flanks of nu/nu CD1 mice. After administering 
an intravenous injection of the bacterial sample, a magnetic guidance was applied toward the 
right flank xenograft. Even in a worse case experiment where the MTB were injected far from the 
targeted tumour sites (injection performed at the tail), efficient targeting at a pre-defined zone 
was achieved. The experimental results also show that applying a lower intensity magnetic pole 
as depicted inside the other xenograft can control a dose. 
While metastatic cancers most often require systemic therapy, there are specific contexts in 
which more effective localized therapy would have major impact on both quality of life and 
survival. Navigation the MTB to the tumours is a first step toward building a new localized 
therapeutic vector for cancer therapy. However, the MTB alone do not have any therapeutic 
effects and their surface has to be functionalized in order to make them a transporter of drugs to 
tumours. Combining existing treatment such as radiotherapy with the MTB could enhance the 
final therapy outcome through sensitizing the tumours to the radiation.  
To date, there is no magic way to treat cancer. Doctors dispose of many tools that they apply 
depending on the disease location, advancement, and the patient tolerance to the side effects of 
the therapy. The concept of magnetotactic bacteria targeting tumour is not the missing magic way 
to treat cancer, however, it can be an additional tool for doctors to help patients that are 
inadmissible to other treatments. 
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